Document:

Exhibit 10.98

                           ADVISORY SERVICES AGREEMENT

THIS Agreement ("Agreement"), effective as of September 1, 2007 is entered into
by and between Gene Logic Inc. ("GLGC"), with a place of business at 50 West
Watkins Mill Road, Gaithersburg, Maryland 20878, and Louis Tartaglia, whose
address is at 32 Manor House Road, Newton, MA. 02459 ("Adviser").

     In consideration of the representations and agreements contained herein,
Adviser and GLGC agree as follows:

     1.  Purpose: GLGC is in the business of providing services to the
         pharmaceutical and biotechnology industries. Such services are provided
         in part through GLGC's Drug Repositioning Division, which uses its drug
         indication discovery platform to identify and develop new or expanded
         uses for small molecule therapeutics. Potential alternative therapeutic
         uses are then validated through animal studies and may then be further
         developed and tested with the goal of commercializing such new uses
         discovered by GLGC. The Drug indication discovery platform may also
         have other potential uses, such as to expand indications for customers'
         currently marketed drugs, and prioritize and identify new or confirm
         known indications for compounds. These activities are collectively
         referred to herein as GLGC's Drug Repositioning business.

         Adviser was previously the General Manager of GLGC's Drug Repositioning
         Division and has special expertise in the field of drug repositioning.
         GLGC wishes to obtain advisory services from Adviser and Adviser is
         willing to provide services to GLGC. The purpose of this Agreement is
         to establish the terms upon which such services will be provided.

     2. Services.

              a.  Subject to the terms and conditions of this Agreement, GLGC
                  hereby appoints Adviser as a special adviser to its Drug
                  Repositioning business and Adviser hereby accepts such
                  appointment.
              b.  Adviser agrees that, during the term of this Agreement and any
                  subsequent extension thereto, he will provide his services as
                  requested by GLGC's Chief Executive Officer ("CEO"), Drs.
                  Thomas Barnes and Stephen Donahue or Bethany Mancilla in their
                  roles as executives in GLGC's Drug Repositioning business or
                  any other executive at GLGC designated by the CEO.
              c.  As requested with respect to GLGC's Drug Repositioning
                  business, in conjunction with GLGC's Board of Directors and
                  members of GLGC's senior management team, Adviser will,

                         i.   evaluate strategic alternatives;
                         ii.  recommend strategic policy decisions;
                         iii. critique proposed strategic initiatives;
                         iv.  refer GLGC to potential new business opportunities
                              appropriate to the Drug Repositioning business;
                         v.   introduce and facilitate new business and
                              financial connections intended to facilitate
                              development of the Drug Repositioning business;
                         vi.  participate in any relevant discussions/meetings
                              with GLGC partners or customers;
                         vii. advise on scientific data interpretation and
                              presentation;
                         viii. otherwise advise GLGC with respect to GLGC's Drug
                              Repositioning activities; and
                         ix.  provide such other services as may be mutually
                              agreed by the parties

<PAGE>

              d.  The services may be provided by meetings or by telephone,
                  e-mail or other written communication. If requested, Adviser
                  will meet or communicate with GLGC representatives or
                  customers of GLGC at times and places to be mutually agreed.

              e.  Adviser shall provide services to GLGC based on the
                  proprietary and/or confidential information provided by GLGC
                  and/or developed by Adviser in the course of providing
                  services hereunder and shall devote such time as reasonably
                  necessary to provide the requested services. Subject to the
                  provisions of Section 10, Adviser agrees to perform the
                  services in a timely and professional manner consistent with
                  industry standards.

     3. Compensation.

              a.  In consideration for the services during the term of this
                  Agreement and while this Agreement is in force, Adviser shall
                  receive:

                         i.   a retainer at a rate of $25,000 per year payable
                              in arrears in quarterly installments, and
                         ii.  payment for specific services at a rate of
                              one-hundred-fifty dollars ($150.00) per hour of
                              Adviser's time devoted to providing services, but
                              not more than $1,200 per day.

                  Adviser shall submit an invoice for his services to GLGC on a
                  monthly basis within thirty days after the end of each month
                  in which services are provided hereunder, showing by date the
                  hours worked, the services provided and the GLGC executive
                  with or for whom the work was performed. GLGC shall pay
                  Adviser for his services within thirty (30) days of receiving
                  each invoice. Adviser will obtain CEO's prior written approval
                  if the hourly rate compensation for services provided in any
                  calendar month are expected to exceed $4,000.00, before
                  providing services that exceed such limit.
              b.  Adviser will also be reimbursed for all reasonable and
                  necessary out-of-pocket expenses (including travel, lodging,
                  and the like), which are incurred at the request of and
                  approved in writing in advance by GLGC, provided any travel
                  expenses comply with GLGC's travel policy, a copy of which is
                  available upon request.

     4.  Confidentiality. In view of GLGC's proprietary rights and interests
         concerning its facilities and technology, Adviser agrees that during
         the term of this Agreement and any subsequent extension(s) thereto and
         for a period of five (5) years thereafter, Adviser agrees to keep
         strictly confidential and not use for his own benefit or for the
         benefit of any third party any information which he may acquire
         relating to GLGC's business, whether such information is disclosed or
         made known by GLGC to Adviser or is generated by Adviser in the course
         of performing the services hereunder. By way of illustration and not
         limitation, such shall include all information, communicated by any
         means, relating to the business of GLGC that is not available to the
         general public, including its technical and business information,
         assets, inventions, know-how, research programs, biological materials,
         processes, drug compound hypotheses, designs, trade secrets, contracts,
         improvements, discoveries, databases, software programs, development
         tools, budgets and unpublished financial information, licenses, and
         other data, both technical and non-technical, prospects, protocols, and
         other information associated with this Agreement and the methods by
         which GLGC uses its indication seeking technologies.

         Adviser shall not disclose such information to any third party or use
         such information for any purpose, except as provided herein, without
         the prior written approval of GLGC. Adviser shall have no obligation
         with respect to any portion of such information which:

<PAGE>

              a.  is or later becomes generally available to the public by use
                  publication or the like, through no fault of Adviser;
              b.  is obtained from a third party who had the legal right to
                  disclose the same to Adviser and who is not under an
                  obligation of confidentiality to GLGC; or
              c.  Adviser already possesses, as evidenced by written records,
                  predating receipt thereof from GLGC provided that this
                  exception shall not apply to any information received or
                  developed by Adviser during his prior employment by GLGC or by
                  Millennium Pharmaceuticals, Inc and its affiliates to the
                  extent that such information subsequently became the property
                  of GLGC and was confidential at the time it became the
                  property of GLGC.

         Specific information disclosed to Adviser by GLGC shall not be deemed
         to be available to the public or in prior possession of Adviser merely
         because such specific information is embraced by more general
         information available to the public or in prior possession of Adviser.

         Adviser also acknowledges that the confidential information to which he
         may have access as a result of the relationship with GLGC described
         herein may constitute material non-public information and that he may
         not trade in the securities of GLGC or assist others to do so on the
         basis of such material non-public information and that he may not
         disclose such information to third parties who might trade on such
         information.

     5.  New Developments. Adviser agrees that any information, including but
         not limited to discoveries, inventions, innovations, suggestions,
         know-how, ideas and reports made by Adviser which either results from
         information disclosed by GLGC, or is developed as a result of Adviser's
         services under this Agreement ("New Developments"), shall become the
         sole property of GLGC without further compensation to Adviser and shall
         be promptly disclosed to GLGC. Adviser will treat such new developments
         as information which is subject to the confidentiality provisions of
         Paragraph 3 herein. GLGC shall own all right, title and interest in and
         to all New Developments under this Agreement.

     6.  Patent Rights and Licenses. If patentable subject matter results from
         services provided hereunder, Adviser shall assist GLGC in the
         preparation and prosecution of appropriate patent applications and
         shall without further compensation execute appropriate documents
         acknowledging the assignment of his rights in such subject matter and
         applications to GLGC. All expenses incidental to the filing and
         prosecution of any such patent applications shall be borne by GLGC. The
         disclosure of proprietary information by GLGC to Adviser shall not
         result in any obligation to grant Adviser any rights in and to said
         proprietary subject matter.

     7.  Third-Party Confidential Information. Adviser agrees that during the
         term of this Agreement, he will not disclose to GLGC any information
         that is confidential or proprietary to any third party.

     8.  Non-Compete/Non-Solicitation. While this Agreement is in effect and for
         one year after this Agreement ends, Adviser agrees that he will not
         assist third parties to develop, market or sell Drug Repositioning
         services to be offered to pharmaceutical and/or biotechnology companies
         as a service or as a collaborative arrangement or in any similar
         relationship that will compete in the marketplace with GLGC's Drug
         Repositioning business. Adviser further agrees that, during the term of
         this Agreement and for one (1) year after the date of termination of
         the Agreement regardless of the reason for termination, Adviser will
         not induce or solicit any employee of GLGC to leave the employ of GLGC
         or assist any third party to do so.

     9.  Term and Termination. This Agreement shall be effective for a
         twelve-month period beginning as of September 1, 2007, and may be
         extended in writing by mutual consent of the parties. However, either
         party may terminate this Agreement at any time upon sixty (60) days'
         prior written notice. Any rights or obligations set forth herein which
         are accrued prior to the termination of this Agreement as well as any
         sections intended by their nature to survive, including but not limited
         to Sections 4, 5, 6 and 8, shall survive termination or expiration of
         this Agreement. Upon termination or expiration of this Agreement,
         Adviser shall promptly return to GLGC all GLGC documentation, property,
         data and related information, along with any copies thereof.

<PAGE>

     10. Other Employment. Adviser is a principal with Third Rock Ventures, LLC
         ("Third Rock"), and has and will continue to have substantial duties to
         Third Rock (including its portfolio companies). Adviser confirms that
         he has determined that Third Rock will not object to the services to be
         provided hereunder. Any services requested hereunder shall be scheduled
         so as not to interfere with Adviser's work at Third Rock (including
         work with Third Rock's portfolio companies). Adviser and represents
         that he believes he will be able to perform duties requested hereunder
         without significant conflict with his duties at Third Rock (or its
         portfolio companies). If at any time Adviser believes that his
         obligations under this Agreement could conflict in a material respect
         with his duties to Third Rock (or its portfolio companies), Adviser
         agrees to notify GLGC's CEO so that the parties can determine if there
         is a way to adjust his work under this Agreement so that it is not in
         conflict with his duties to Third Rock (and its portfolio companies).
         If such conflict cannot be resolved to the reasonable satisfaction of
         both parties to this Agreement, then either party may terminate this
         Agreement by written notice to the other.

     11. Miscellaneous:

              a.  Independent Contractor. For the purposes of this Agreement,
                  Adviser shall be an independent contractor without the
                  authority to bind or act as agent for GLGC or its employees
                  for any purpose. All taxes and social security payments due
                  with respect to any compensation paid pursuant to this
                  Agreement shall be the sole responsibility of Adviser.

              b.  Assignment. This Agreement is a contract for personal services
                  by Adviser in recognition of his special expertise and
                  experience; the performance of such personal services may not
                  be assigned or delegated.

              c.  Governing Law. This Agreement shall be construed in accordance
                  with the laws of the State of Maryland. Adviser hereby
                  expressly consents to the personal jurisdiction of the state
                  and federal courts located in Maryland for any lawsuit filed
                  there against him/her by GLGC arising from or relating to this
                  Agreement

              d.  Warranties. The parties warrant and represent that they have
                  the right to enter into this Agreement. Adviser further
                  warrants and represents that the terms of this Agreement are
                  not inconsistent with other contractual obligations, express
                  or implied, which he may have.

              e.  Amendments. No modification to this Agreement shall be
                  effective unless made in writing and duly executed by or on
                  behalf of each party.

              f.  Entire Agreement. This Agreement constitutes the entire
                  agreement between the parties with respect to the services to
                  be provided by Adviser hereunder superseding all prior
                  agreements and understandings between the parties (whether
                  written or oral) relating to said subject matter. However,
                  this Agreement does not modify, waive or alter any of the
                  obligations of the parties under prior agreements relating to
                  the previous employment of Adviser by GLGC.

<PAGE>

              g.  Counterparts. This Agreement may be executed in two or more
                  counterparts, including by facsimile transmission, each of
                  which shall be deemed an original, but all of which together
                  shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the dates set
forth below.

               Gene Logic Inc.                         Louis Tartaglia

By:    /s/ Charles L. Dimmler, III            /s/ Louis A. Tartaglia
       ----------------------------------     ----------------------------------
       Charles L. Dimmler, III, President

Date:  September 19, 2007                     Date   September 21, 2007Exhibit 10.99

Exhibit 10.99 - Asset Purchase Agreement

1

================================================================================

                            ASSET PURCHASE AGREEMENT

                                 by and between

                                 GENE LOGIC INC.

                                  (as Company)

                                       and

                           OCIMUM BIOSOLUTIONS LIMITED

                                   (as Parent)

                                       and

                            OCIMUM BIOSOLUTIONS INC.

                                 (as Purchaser)

                                   dated as of

                                October 14, 2007

================================================================================

<PAGE>

                                TABLE OF CONTENTS

                            ASSET PURCHASE AGREEMENT

ARTICLE I  PURCHASE AND SALE OF ASSETS.......................................1

  Section 1.01.   Purchase and Sale of Assets................................1

  Section 1.02.   Obligations and Liabilities................................3

  Section 1.03.   Purchase Price; Payment of Purchase Price..................6

  Section 1.04.   Allocation.................................................9

  Section 1.05.   Closing...................................................10

  Section 1.06.   Closing Obligations.......................................10

ARTICLE II  REPRESENTATIONS AND WARRANTIES OF PURCHASER.....................13

  Section 2.01.   Corporate.................................................13

  Section 2.02.   Authority.................................................13

  Section 2.03.   No Violation..............................................14

  Section 2.04.   Brokers...................................................14

  Section 2.05.   Financing.................................................14

  Section 2.06.   Litigation................................................14

  Section 2.07.   Limitations of Company's Representations..................15

  Section 2.08.   Disclosure Documents......................................15

  Section 2.09.   Financial Statements......................................15

ARTICLE III  REPRESENTATIONS AND WARRANTIES OF COMPANY......................15

  Section 3.01.   Corporate.................................................16

  Section 3.02.   Authority.................................................16

  Section 3.03.   No Violation..............................................16

  Section 3.04.   Tax Matters...............................................17

  Section 3.05.   Absence of Certain Changes................................17

  Section 3.06.   No Litigation.............................................18

  Section 3.07.   Compliance with Laws and Orders; Environmental Laws.......18

  Section 3.08.   Properties................................................19

  Section 3.09.   Tangible Personal Property................................19

  Section 3.10.   Real Property.............................................19

  Section 3.11.   Insurance.................................................20

  Section 3.12.   Material Contracts........................................20

                                       i
<PAGE>

  Section 3.13.   Labor Matters.............................................22

  Section 3.14.   Employee Benefit Plans....................................22

  Section 3.15.   Intellectual Property.....................................23

  Section 3.16.   Financial Statements......................................25

  Section 3.17.   Brokers...................................................25

  Section 3.18.   Inventory.................................................26

  Section 3.19.   Customers and Suppliers...................................26

  Section 3.20.   Transactions with Related Persons.........................26

  Section 3.21.   Product Warranties........................................26

  Section 3.22.   Sufficiency of Assets.....................................27

  Section 3.23.   Contract Rights...........................................27

ARTICLE IV  COVENANTS.......................................................27

  Section 4.01.   Conduct of Business by Company Pending the Closing........27

  Section 4.02.   No Solicitation...........................................28

  Section 4.03.   Access to Information.....................................29

  Section 4.04.   Notification of Certain Matters...........................30

  Section 4.05.   Public Announcements......................................31

  Section 4.06.   Commercially Reasonable Efforts; Cooperation..............31

  Section 4.07.   Retention of Books and Records............................32

  Section 4.08.   Expenses; Proration.......................................33

  Section 4.09.   Assignment of Contracts, Rights, etc......................33

  Section 4.10.   Transfer Taxes and Recording Fees.........................34

  Section 4.11.   Tax Matters...............................................34

  Section 4.12.   Mail Received After Closing...............................35

  Section 4.13.   Personnel Matters.........................................35

  Section 4.14.   Non-Solicitation and Non-Compete..........................37

  Section 4.15.   Minimum Conditions for Assignment of Lease................38

ARTICLE V  CONDITIONS TO OBLIGATIONS OF PURCHASER AND PARENT................38

  Section 5.01.   Representations and Warranties............................38

  Section 5.02.   Performance of this Agreement.............................38

  Section 5.03.   Consents and Approvals....................................38

  Section 5.04.   Injunction, Litigation, etc...............................38

  Section 5.05.   Legislation...............................................38

                                       ii
<PAGE>

  Section 5.06.   Deliveries................................................38

  Section 5.07.   Matters Disclosed Pursuant to Section 4.04................39

  Section 5.08.   Stockholder Approval......................................39

  Section 5.09.   No Material Adverse Change................................39

ARTICLE VI  CONDITIONS TO OBLIGATIONS OF COMPANY............................39

  Section 6.01.   Representations and Warranties............................39

  Section 6.02.   Performance of this Agreement.............................39

  Section 6.03.   Stockholder Approval......................................39

  Section 6.04.   Consents and Approvals....................................39

  Section 6.05.   Injunction, Litigation, etc...............................39

  Section 6.06.   Legislation...............................................40

  Section 6.07.   Deliveries................................................40

ARTICLE VII  INDEMNIFICATION................................................40

  Section 7.01.   Indemnification by Company................................40

  Section 7.02.   Indemnification by Purchaser and Parent...................40

  Section 7.03.   Survival Date.............................................40

  Section 7.04.   Limitations on Indemnification............................41

  Section 7.05.   Definition of Loss........................................42

  Section 7.06.   Notice of Claims..........................................43

  Section 7.07.   Third Party Claims........................................43

  Section 7.08.   Subrogation Rights; No Duplication........................44

  Section 7.09.   Exclusive Remedies........................................45

  Section 7.10.   Indemnity Offset..........................................45

ARTICLE VIII  TERMINATION, AMENDMENT AND WAIVER.............................45

  Section 8.01.   Termination...............................................45

  Section 8.02.   Effect of Termination.....................................46

  Section 8.03.   Amendment.................................................46

  Section 8.04.   Extension; Waiver.........................................46

ARTICLE IX  POST-CLOSING AGREEMENTS.........................................47

  Section 9.01.   Severance Obligations.....................................47

  Section 9.02.   Release of Guarantees, Security Agreement and Escrow
  Funds           48

ARTICLE X  GENERAL PROVISIONS...............................................48

  Section 10.01.  Limitation on Warranties..................................48

                                      iii
<PAGE>

  Section 10.02.  Expenses..................................................49

  Section 10.03.  Entire Agreement..........................................49

  Section 10.04.  Assignment................................................49

  Section 10.05.  Parties in Interest.......................................49

  Section 10.06.  Validity..................................................49

  Section 10.07.  Notices...................................................50

  Section 10.08.  Law Governing Agreement; Jurisdiction; Jury Trial
  Waiver          51

  Section 10.09.  Enforcement of Agreement..................................51

  Section 10.10.  Bulk Sales................................................52

  Section 10.11.  Headings..................................................52

  Section 10.12.  Counterparts..............................................52

  Section 10.13.  Definitions...............................................52

Exhibits:
---------

      1.03(b)(ii).......Form of Promissory Note
      1.03(b)(iii)(A)...Form of Guarantee
      1.03(b)(iii)(B)...Form of Security Agreement
      1.03(b)(iii)(C)...Form of Escrow Agreement
      1.03(c)...........Initial Listing of Assets and Liabilities
      1.06(a)(i)........Form of Bill of Sale
      1.06(a)(ii).......Form of Assignment and Assumption Agreement
      1.06(a)(iii)(A)...Form of Trademark Assignment
      1.06(a)(iii)(B)...Form of Patent Assignment
      1.06(a)(iv).......Form of Third Party IP Assignment and Assumption
                        Agreement
      1.06(a)(v)........Form of 50 West Watkins Lease Assignment and
                              Assumption Agreement
      1.06(a)(vi).......Form of Sublease
      1.06(a)(vii)......Form of Drug Repositioning License Agreement
      1.06(a)(viii).....Form of Diagnostic Development License Agreement
      1.06(a)(ix).......Form of Drug Repositioning MSA Agreement
      1.06(a)(x)........Form of Diagnostic Development MSA Agreement
      1.06(a)(xi).......Form of Transition Services Agreement
      3.15(h)...........Form of Proprietary Information and Inventions
      Agreement

Schedules:
----------

      1.01(b)(1)........Retained Diagnostic Development Assets
      1.01(b)(2)........Retained Drug Repositioning Business Assets
      1.01(b)(3)        Retained Corporate Assets

                                       iv
<PAGE>

      2.05..............Financing Letter
      3.03(a)...........Violations
      3.04(c)...........Tax Returns
      3.05..............Certain Changes
      3.06..............Litigation
      3.07(a)...........Laws and Orders
      3.07(b)...........Operating Permits
      3.08..............Title to Property
      3.09(a)(1)........Equipment
      3.09(a)(2)........Material Equipment
      3.10(a)...........Leased Real Property
      3.11..............Insurance
      3.12(a)...........Material Contracts
      3.12(b)...........Material Contracts - Bona Fide Transaction,
      Ordinary
                        Course, and Binding and Enforceability
      Exceptions
      3.13..............Employee and Labor Matters
      3.14(a)...........Employee Benefit Plans
      3.15(a)...........Registered IP
      3.15(b)...........Intellectual Property Rights
      3.15(c)...........Biorepository Rights
      3.15(d)...........Open Source Licenses
      3.15(e)...........Business Intellectual Property Rights
      3.15(f)...........Maintenance
      3.15(h)...........Inventorship by Employees and Consultants
      3.15(i)...........Intellectual Property Claims
      3.15(j)...........Infringement or Misappropriation by Company
      3.15(k)...........Infringement or Misappropriation by Others
      3.16(c)...........Other Current Liabilities of the Business
      3.16(e)...........Subsidiary Balance Sheets
      3.19(a)...........Material Customers
      3.19(b)...........Material Suppliers
      3.20..............Transactions with Related Persons
      4.13(a)...........Employees of the Business
      4.13(b)...........Severance Benefits
      9.01(a)...........Company Severance Policies
      10.13(a)..........Excluded 3rd Party Software Licenses
      10.13(b)..........Assigned Patents
      10.13(c)..........Permitted Encumbrances

                                       v
<PAGE>

                            ASSET PURCHASE AGREEMENT

            This ASSET PURCHASE AGREEMENT, dated as of October 14, 2007 (the
"Agreement"), is made by and between Gene Logic Inc., a Delaware corporation
(the "Company"), and Ocimum Biosolution Limited, a company incorporated under
the Company Act, 1956 in the Republic of India ("Parent"), and Ocimum
Biosolutions Inc., a Delaware corporation ("Purchaser"). Company, Parent and
Purchaser are referred to herein individually as a "Party" and collectively as
the "Parties."

                                     RECITAL

      The Company engages in the business of developing, operating and licensing
databases of genomic data and related software and providing genomic and genetic
data generation and analysis services and other related services (the
"Business," as that term is more fully defined in Section 10.13). Purchaser
desires to purchase and assume, and Company desires to sell and assign (i)
substantially all of Company's assets that relate primarily to the Business and
(ii) certain specifically enumerated liabilities relating to the Business on the
terms and subject to the conditions set forth in this Agreement. The term
"Business" does not include any part of the Company's Diagnostic Development
Business, Drug Repositioning Business or corporate Shared Services Division.
Capitalized terms shall have the meanings set forth in Section 10.13.

            NOW, THEREFORE, in consideration of the foregoing and the mutual
covenants and agreements herein contained, and intending to be legally bound
hereby, Company and Purchaser hereby agree as follows:

                                    ARTICLE I
                           PURCHASE AND SALE OF ASSETS

            Purchase and Sale of Assets. (a) (a) Subject to the terms and
conditions of this Agreement, at the Closing, Company agrees to sell to
Purchaser, Purchaser agrees to purchase, and Parent agrees to cause Purchaser to
purchase, from Company all the right, title and interest of Company and its
Affiliates free and clear of all Liens except for Permitted Encumbrances, in and
to the following assets used or held for use by or for the Business ("Acquired
Assets"):

                  (i) the Biorepository;

                  (ii) the Business Intellectual Property;

                  (iii) the Inventory as of the Effective Time;

                  (iv) the Equipment;

                  (v) the Contracts;

                  (vi) the Open Purchase Orders as of the Effective Time;

                                       1
<PAGE>

                  (vii) the 50 West Watkins Mill Road Lease (but excluding any
      obligations or liabilities prior, or with respect to periods prior to, the
      Effective Time);

                  (viii) the Leasehold Improvements;

                  (ix) the Third Party IP, to the extent assignable without more
      than a nominal cost to Company, and subject to the terms in the applicable
      licenses;

                  (x) the Business Information, subject to the Seller's right to
      retain a copy of such material and use and modify it to comply with
      applicable Law or with a third party agreement;

                  (xi) the Employee Information;

                  (xii) to the extent assignable, the Operating Permits;

                  (xiii) to the extent assignable, the Environmental Permits

                  (xiv) to the extent assignable, the Equipment Warranties;

                  (xv) the Prepaid Expenses;

                  (xvi) the Company's intercompany accounts receivable relating
      to Company's Subsidiaries in Japan and the United Kingdom as of the
      Effective Time;

                  (xvii) all issued and outstanding capital stock of Company
      Subsidiaries; and

                  (xviii) to the extent not included elsewhere in the this
      Section 1.01(a) the list identifying Company's clinical network as it
      exists on or prior to the Closing Date and associated information.

            (b) Retained Assets. The Parties acknowledge and agree that, except
as specifically listed in Section 1.01(a), the Acquired Assets shall not include
any assets of the Company that are not necessary for the conduct of the Business
as it has been conducted during the twelve (12) months prior to the date of this
Agreement and is currently being conducted by the Company, including without
limitation, the following ("Retained Assets"):

                  (i) any cash and cash equivalents, accounts and notes
      receivable and securities (excluding capital stock of Affiliates) of
      Company or any of its Affiliates (including all intercompany and
      intracompany receivables other than the intercompany accounts receivable
      relating to Company's Subsidiaries in Japan and Europe), all bank account
      balances and all petty cash) and security deposits or advances deposited
      or paid by or on behalf of Company as lessee, sublessee or guarantor or
      pursuant to any Real Property Leases;

                                       2
<PAGE>

                  (ii) any amounts payable to or claims or causes of action of
      Company or any of its Affiliates in respect of Taxes, including duty
      drawbacks, Tax credits and Taxes refundable to Company or any of its
      Affiliates in respect of transactions prior to the Effective Time or in
      respect of the period or portion thereof ending on or prior to the
      Effective Time;

                  (iii) any refunds due from, or payments due on, claims with
      the insurers of Company or any of its Affiliates in respect of losses
      arising prior to the Effective Time;

                  (iv) all books, documents, records and files prepared in
      connection with or relating to the transactions contemplated by this
      Agreement, including bids received from other parties and analyses
      relating to the Business;

                  (v) such portion of the Business Information that Company or
      its Affiliates are, in the reasonable opinion of Company's counsel,
      required by Law or by agreement with a third party to retain, provided
      that Purchaser shall be provided copies of such material unless contrary
      to Law or agreement with a third party;

                  (vi) any asset of Company or any of the its Affiliates that
      would constitute an Acquired Asset if it were owned by Company on the
      Closing Date that is conveyed or otherwise disposed of during the period
      from the date hereof until the Closing Date (x) in the ordinary course of
      business and not in violation of the terms of this Agreement, (y) as
      otherwise expressly permitted by the terms of this Agreement or (z) with
      the written consent of Purchaser;

                  (vii) the Company Benefit Plans;

                  (viii) those items listed on Schedule 1.01(b)(i) (Retained
      Diagnostic Development Assets), 1.01(b)(ii) (Retained Drug Repositioning
      Asset) and 1.01(b)(iii) (Retained Corporate Assets); and

                  (ix) any asset of Company that is used primarily in connection
      with the Drug Repositioning Business or the Diagnostic Development
      Business.

            Section 1.02.      Obligations and Liabilities.
                               ---------------------------

            (a) Assumed Liabilities. Subject to the terms and conditions of this
Agreement, at the Closing, Purchaser will assume, and Parent will cause
Purchaser to assume, from the Company and its Affiliates, and thereafter pay,
perform or discharge in accordance with their terms the following liabilities
("Assumed Liabilities"):

                                       3
<PAGE>

                  (i) all obligations or liabilities of Company or any of its
      Affiliates with respect to accrued and unused paid time off, as set out in
      Schedule 4.13 of Business Employees as at the Effective Time;

                  (ii) the accrued welfare benefits, accrued benefits and
      payroll liabilities and all accrued self-insurance health care benefits as
      provided on the Closing Listing of Assets and Liabilities (the "Accrued
      Benefits Liabilities"); provided, however, that in the event that the
      aggregate amount of such Accrued Benefits Liabilities exceeds $205,500 no
      benefit or liability in excess of $205,500 shall be, or be deemed to be,
      an Assumed Liability;

                  (iii) all executory obligations and liabilities in the
      ordinary course of Business of Company or any of its Affiliates arising
      from or in connection with (x) the Open Purchase Orders, and (y)
      Purchaser's undertaking and assumption of obligations and liabilities with
      respect to events arising from and after the Closing Date with regard to
      all of the Contracts included in the Acquired Assets;

                  (iv) all of the Company's intercompany accounts payable
      relating to Company's Subsidiaries in Japan and Europe as of the Effective
      Time; and

                  (v) personal property taxes, other ad valorem taxes, with
      respect to the Assets and any other liabilities or obligations relating to
      Taxes for any period or portion thereof of a tax year or period ending
      after the Effective Time. For the avoidance of doubt, such Taxes for the
      year that includes the Closing Date shall be allocated pro rata based on
      the number of days that occur before and after the Closing, with such
      Taxes being borne by the Seller based on the ratio of the number of days
      in the relevant period prior to and including the Closing Date to the
      total number of days in the actual taxable period with respect to which
      such Taxes are assessed, irrespective of when such Taxes are due, become a
      lien or are assessed, and such Taxes being borne by the Purchaser based on
      the ratio of the number of days in the relevant period after the relevant
      Closing Date to the total number of days in the actual taxable period with
      respect to which such Taxes are assessed, irrespective of when such Taxes
      are due, become a lien or are assessed.

            (b) Retained Liabilities. Notwithstanding anything in this Section
1.03(b) or elsewhere in this Agreement or any other Transaction Document to the
contrary, the Assumed Liabilities shall not include, and neither the Purchaser
nor any of its Affiliates will assume at the Closing, any of the following
liabilities or obligations (collectively, "Retained Liabilities"):

                  (i) liabilities or obligations for indebtedness for borrowed
      money or guarantees, or other financial assistance obligations incurred by
      the Seller or any of its Affiliates or relating to the Business or the
      Assets;

                                       4
<PAGE>

                  (ii) liabilities or obligations with respect to products or
      services delivered by Seller prior to the Effective Time (in the case of
      subscription services, delivery shall be deemed to occur continuously);

                  (iii) liabilities or obligations of Company or any of its
      Affiliates to its lawyers, accounts, investment advisors and consultants
      relating to the execution, delivery and consummation of this Agreement and
      the transactions contemplated hereby and thereby;

                  (iv) liabilities or obligations of Company or any of its
      Affiliates relating to Taxes for any period or portion thereof ending on
      or before the Effective Time;

                  (v) except as specified otherwise in Section 1.02(a)(i) of
      this Agreement or as may otherwise be required by Law, the liabilities or
      obligations of Company or any of its Affiliates that relate to or arise
      from or in connection with the employment or termination of employment by
      Company of any of the Business Employees prior to Closing Date, or the
      employment or termination of employment of any of Company's employees who
      are not Business Employees;

                  (vi) the Environmental Liabilities of Company;

                  (vii) any amounts owing prior to, or with respect to periods
      prior to, or goods purchased or services performed prior to, the Closing
      pursuant to any Contract, 3rd Party Software License or Real Property
      Lease, except with respect to Open Purchase Orders;

                  (viii) any liabilities or obligations of Company relating to,
      in connection with or arising under the Retained Assets;

                  (ix) all Accrued Benefits Liabilities in excess of $205,500,
      if and to the extent the aggregate amount of such liabilities is greater
      than $205,500; and

                  (x) all obligations and liabilities of the Company with
      respect to events arising prior to the Closing Date with regard to all of
      the Contracts included in the Acquired Assets;

                  (xi) any and all other liabilities or obligations of Company
      or any of its Affiliates, whether known or unknown, accrued, absolute,
      contingent, determined, determinable or otherwise, that are not expressly
      assumed by the Purchaser or the Purchaser's Affiliates pursuant to Section
      1.03(a), but in no event including liabilities of the Business arising in
      connection with the operation of the Business from and after Closing.

                                       5
<PAGE>

            Section 1.03.      Purchase  Price;  Payment  of  Purchase
Price.

            (a) Purchase Price. The consideration to be paid for the Acquired
Assets (the "Purchase Price") shall be (i) Ten Million Dollars ($10,000,000),
plus or minus the Purchase Price Adjustment (the "Total Cash Consideration"),
(ii) the assumption of the Assumed Liabilities, and (iii) the granting of the
licenses provided for in the Drug Repositioning License Agreement and the
Diagnostic Development License Agreement.

            (b) Payment of Purchase Price. At the Closing, the Purchase Price,
shall be delivered by Parent and Purchaser to Company as follows:

                  (i) Seven Million Dollars ($7,000,000) (the "Closing Cash
      Payment") shall be wired via Federal Fund transfer to Company's account as
      set forth in written wire transfer instructions to be delivered to
      Purchaser by Company at or prior to Closing

                  (ii) Delivery by Parent and Purchaser of a promissory note
      payable in full on the eighteen (18) month anniversary of Closing in
      substantially the form attached hereto as Exhibit 1.03(b)(ii) in the
      principal amount of Three Million Dollars ($3,000,000) (the "Promissory
      Note");

                  (iii) Delivery by Purchaser of either:

                        (X) (A) a guarantee in substantially the form of Exhibit
      1.03(b)(iii)(A) (the "Guarantee") executed by Coramandel Prestcrete
      Private Limited, a company incorporated under the Company Act, 1956, in
      the Republic of India and an affiliate of Parent and Purchaser
      ("Coramandel"), (B) the Security and Patent and Trademark Security
      Agreement in substantially the form of Exhibit 1.03(b)(iii)(B) (the
      "Security Agreement") executed by Purchaser as maker of the Promissory
      Note, (C) Seven-Hundred-Fifty Thousand Dollars ($750,000) deposited with
      the Escrow Agent, together with an escrow agreement executed by Purchaser
      in the form attached hereto as Exhibit 1.03(b)(iii)(C) (the "Escrow
      Agreement"); or

                        (Y) a letter of credit with the following terms (A) in
      an amount not less than Three Million Six-Hundred Thousand Dollars
      ($3,600,000) for the period ending twenty (20) months after Closing or
      upon payment of all amounts payable under the Promissory Note, (B) after
      such twenty-month period, or the payment of all amounts payable under the
      Promissory Note, the amount of such letter of credit may be reduced, on a
      continuous basis, to be not less than the aggregate amount of base rent
      and additional rent under the remaining term of the 50 West Watkins Mill
      Road Lease in the event that the landlord thereunder were to declare an
      event of default under such lease and (C) issued by the United States
      office of any bank organized and doing business under the laws of the
      United States of America or any state thereof, that is subject to
      supervision and examination by federal or state authorities and has a
      combined capital and surplus of at least $750 million as set forth in its
      most recent published annual report of condition in form and substance
      acceptable to Company in its sole and absolute discretion providing for
      payment to Company upon a representation by the Chief Financial Officer of
      the Company in the case of a default under the (I) Promissory Note or (II)
      50 West Watkins Mill Road Lease in the event that Company has not been
      released from any and all obligations under such lease arising from and
      after Closing, and (D) an expiry date not earlier than May 30, 2011 (the
      "Backstop Letter of Credit");

                                       6
<PAGE>

                  (iv) assumption of the Assumed Liabilities by execution and
      delivery of the Assignment and Assumption Agreement, the 50 West Watkins
      Lease Assignment, Assumption Agreement and the Tokyo Lease Assignment and
      Assumption Agreement and the Third Party IP Assignment and Assumption
      Agreements; and

                  (v) the granting by Purchaser to Company of certain
      intellectual property licenses, by execution and delivery of the Drug
      Repositioning License Agreement and the Diagnostic Development License
      Agreement.

The Purchase Price Adjustment shall be determined and paid in accordance with
Section 1.03(c).

            (c) Purchase Price Adjustment.

                  (i) In addition to the terms defined elsewhere in this
      Agreement, for purposes of this Agreement, the following capitalized terms
      shall have the following meanings:

                  "Initial Listing of Assets and Liabilities" means the listing
of certain assets and liabilities of the Business as of June 30, 2007 attached
hereto as Exhibit 1.03(c).

                  "Net Current Assets" means the sum of the Inventory, Prepaid
Assets, Other Current Assets, and Intercompany Receivables for Japan and Europe
subsidiaries relating to the Business as provided on the Initial Listing of
Assets and Liabilities or the Closing Listing of Assets and Liabilities, as
applicable.

                  "Initial Net Current Assets" means the Net Current Assets as
provided on the Initial Listing of Assets and Liabilities.

                  "Closing Net Current Assets" means the Net Current Assets as
of the Closing Date determined in accordance with the Closing Listing of Assets
and Liabilities.

                  "Initial Unbilled Receivables" means the Unbilled Receivables
of the Business as provided on the Initial Listing of Assets and Liabilities
which are equal to Three Million Three-Hundred-Forty-Two Thousand Dollars
($3,342,000).

                                       7
<PAGE>

                  "Closing Unbilled Receivables" means the Unbilled Receivables
of the Business as of the Closing Date as provided on the Closing Listing of
Assets and Liabilities.

                  "Net Current Assets Adjustment" means an amount equal to (i)
the Closing Net Current Assets minus (ii) the Initial Net Current Assets;
provided, however, that if the absolute value of such amount is less than Five
Hundred Thousand Dollars ($500,000), such amount shall be deemed to be Zero
Dollars ($0.00) for purposes of the Purchase Price Adjustment (as defined
below). In addition, for purposes of determining the Purchase Price Adjustment,
if the absolute value of the Net Current Assets Adjustment is greater than Five
Hundred Thousand Dollars ($500,000), then in determining the Net Current Assets
Adjustment Five Hundred Thousand Dollars ($500,000) shall be added to such Net
Current Assets Adjustment amount if such amount is a negative number and Five
Hundred Thousand Dollars ($500,000) shall be subtracted from such Net Current
Assets Adjustment if such amount is a positive number (For Example, if the
Initial Net Current Assets equals $2,700 and the Closing Net Current Assets
equals $2,000, then the Net Current Assets Adjustment for purposes of the
Purchase Price Adjustment calculation shall be -$200).

                  "Net Unbilled Receivable Adjustment" shall be the difference
between the Initial Unbilled Receivables and the Closing Unbilled Receivables,
such that if the absolute value of the Closing Unbilled Receivables is larger
than the absolute value of the Initial Unbilled Receivables, then for purposes
of the Purchase Price Adjustment, such difference shall be a negative amount
which will increase any Purchase Price Adjustment payment to the Purchasers from
Company, if any, or decrease any Purchase Price Adjustment payment to Company
from Purchaser, if any; provided, that if the absolute value of the Closing
Unbilled Receivables is smaller than the absolute value of the Initial Unbilled
Receivables, then for purposes of the Purchase Price Adjustment, such amount
will be treated as equaling Zero Dollars ($0.00). (For example, if the Initial
Unbilled Receivables is -$1,000 and the Closing Unbilled Receivables is -$1,600,
then the Net Unbilled Receivables Adjustment would be equal to -$600).

                   (ii) The "Purchase Price Adjustment" (which may be a positive
or negative number) will be equal to the sum of the Net Current Assets
Adjustment plus the Net Unbilled Receivables Adjustment plus the net book value
of the Agilent Equipment as of the Closing. If the Purchase Price Adjustment is
positive, the Purchase Price Adjustment shall be paid by wire transfer by
Purchaser to an account specified by Company. If the Purchase Price Adjustment
is negative, the Purchase Price Adjustment shall be paid by wire transfer by
Company to an account specified by Purchaser. Within ten (10) Business Days
after the calculation of Net Unbilled Receivables Adjustment and the Net Current
Assets Adjustment becoming binding on the Parties pursuant to Subsection
1.03(c)(iv) below, Purchaser or Company, as the case may be, shall make the wire
transfer payment provided for in this Section 1.03(c)(ii).

                  (iii) Company shall prepare a listing of assets and
liabilities ("Closing Listing of Assets and Liabilities") of the Company as of
the Effective Time in accordance with the Company's past practices and on the
same basis and applying the same methodology, accounting principles, policies
and practices used in preparing the Initial Listing of Assets and Liabilities.
Company shall deliver the Closing Listing of Assets and Liabilities and the
calculation of the Purchase Price Adjustment within thirty-five (35) days
following the Closing Date to Purchaser.

                                       8
<PAGE>

                  (iv) If within thirty (30) days following delivery of the
Closing Listing of Assets and Liabilities, Purchaser has not given Company
written notice of its objection as to the Closing Listing of Assets and
Liabilities (which notice shall state the basis of Purchaser's objection), then
the Closing Listing of Assets and Liabilities shall be binding and conclusive on
the Parties and be used in computing the Purchase Price Adjustment.

                  (v) If Purchaser duly gives Company such notice of objection,
and if Purchaser and Company fail to resolve the issues outstanding with respect
to the Closing Listing of Assets and Liabilities within thirty (30) days of
Company's receipt of Purchaser's objection notice, Purchaser and Company shall
submit the issues remaining in dispute to PricewaterhouseCoopers LLP,
independent public accountants (the "Independent Accountants") for resolution
applying the principles, policies and practices referred to in Section
1.03(c)(iii). If issues are submitted to the Independent Accountants for
resolution, (A) Company and Purchaser shall furnish or cause to be furnished to
the Independent Accountants such work papers and other documents and information
relating to the disputed issues as each party may choose to provide and the
Independent Accountants may request and are available to that Party or its
agents and shall be afforded the opportunity to present to the Independent
Accountants any material relating to the disputed issues and to discuss the
issues with the Independent Accountants; (B) the determination by the
Independent Accountants, as set forth in a notice to be delivered to both
Company and Purchaser within sixty (60) days of the submission to the
Independent Accountants of the issues remaining in dispute, shall be final,
binding and conclusive on the parties and shall be used in the determination of
the Closing Net Current Assets and Closing Unbilled Receivables; and (C) Company
and Purchaser will each bear the percentage of the fees and costs of the
Independent Accountants for such determination equal to (i) the dollar amount
awarded to the other Party in connection with the Independent Accounts
determination, divided by (ii) the total amount in dispute.

            Section 1.04. Allocation. Prior to the Closing, Company and
Purchaser shall use their best efforts to agree in writing to an allocation of
the Purchase Price among the Acquired Assets for all purposes (including Tax and
financial accounting). If Company and Purchaser have not agreed on the
allocation of the Purchase Price prior to Closing, such obligation to use their
best efforts to agree in writing to such an allocation shall continue after
Closing and if Company and Purchaser are unable to agree on such allocation
within sixty (60) days of Closing (or such earlier date as is five (5) days
prior to the due date of IRS Form 8594), Ernst & Young shall be designated to
make such determination and once Ernst & Young makes such determination, it
shall be final and binding on the Parties. The failure of Company and Purchaser
to reach agreement on a Purchase Price allocation shall not constitute grounds
for termination of this Agreement by any Party and agreement by Company and
Purchaser to a Purchase Price allocation shall not be a condition to the
obligation of any Party to consummate the transactions contemplated by this
Agreement. After the Closing, the Parties shall make consistent use of such
allocation for all Tax purposes and in all filings with, and declarations and
reports to, the IRS and relevant state agencies in respect thereof, including
reports required to be filed under the Code. Purchaser shall prepare and deliver
IRS Form 8594 to Company within forty-five (45) days after the Closing Date to
be filed with the IRS. In any proceedings related to the determination of any
Taxes, neither Company nor Purchaser shall contend or represent that such
allocation is not a correct allocation.

                                       9
<PAGE>

            Section 1.05. Closing. The purchase and sale provided for in this
Agreement (the "Closing") will take place at the office of Gene Logic Inc.
located at 50 West Watkins Mill Road, Gaithersburg, Maryland as promptly as
reasonably possible, but in any event no later than the fifth (5th) Business Day
following the day upon which all of the conditions to Closing have been
satisfied or waived (other than those conditions which by their terms cannot be
satisfied until the Closing), with a target Closing Date of December 14, 2007,
but in no event after December 31, 2007, unless delayed due to a delay in
distributing the Proxy Statement due to SEC review of the Proxy Statement or
other Company filings which is ongoing after November 20, 2007 (the "Closing
Date"), unless otherwise specifically agreed in writing signed by each of the
Parties. The Closing and all of the transactions contemplated by this Agreement
shall be deemed to have occurred simultaneously and become effective as of 12:01
a.m. (local time) on the Closing Date (the "Effective Time").

            Section 1.06. Closing Obligations. In addition to any documents to
be delivered under other provisions of this Agreement, at the Closing:

            (a) Company shall deliver to Purchaser:

                  (i) a bill of sale for all the Acquired Assets (other than the
      Contracts, the Real Estate Leases, Third Party IP and the Registered IP)
      in the form of Exhibit 1.06(a)(i) (the "Bill of Sale") executed by
      Company;

                  (ii) an assignment of all of the Contracts included in the
      Acquired Assets in the form of Exhibit 1.06(a)(ii), which assignment shall
      also contain Purchaser's undertaking and assumption of obligations and
      liabilities with respect to events arising from and after the Closing Date
      (the "Assignment and Assumption Agreement") executed by Company;

                  (iii) a recordable assignment of all (A) the trademarks
      included in the Registered IP in the form of Exhibit 1.06(a)(iii)(A) (the
      "Trademark Assignment"), (B) the patents and patent applications included
      in the Registered IP in the form of Exhibit 1.06(a)(iii)(B) (the "Patent
      Assignment"), and (C) a limited power of attorney in form and substances
      satisfactory to both Parties authorizing Purchaser to undertake with the
      appropriate registrars the registrant name change process with respect to
      the domain names transferred to Purchaser pursuant to this Agreement in
      accordance with the transition plan agreed to by the Parties pursuant to
      the Transition Services Agreement, executed by the Company;

                                       10
<PAGE>

                  (iv) assignment and assumption of the Third Party IP,
      assigning Company's right thereunder to Purchaser, executed by Company in
      the form attached hereto as Exhibit 1.06(a)(iv), including where available
      and if obtainable prior to Closing at no more than a nominal cost to
      Company, any necessary licensor consents to assignment required under the
      applicable license agreement, which assignment shall also contain
      Purchaser's undertaking and assumption, of obligations and liabilities
      with respect to events arising from and after the Closing Date, of the
      Third Party IP (the "Third Party IP Assignment and Assumption
      Agreements");

                  (v) an assignment and assumption agreement assigning the 50
      West Watkins Mill Road Lease in the form of Exhibit 1.06(a)(v), executed
      by Company and the landlord, which assignment shall also contain
      Purchaser's undertaking and assumption of obligations and liabilities with
      respect to events arising from and after the Closing Date, of the 50 West
      Watkins Mill Road Lease (the "50 West Watkins Lease Assignment and
      Assumption Agreement");

                  (vi) a sublease agreement between Purchaser, as landlord, and
      Company, as tenant, in the form attached hereto as Exhibit 1.06(a)(vi),
      executed by Company (the "Sublease");

                  (vii) a license agreement between Purchaser, as licensor, and
      Company, as licensee, in the form attached hereto as Exhibit 1.06(a)(vii)
      (the "Drug Repositioning License Agreement") executed by Company, granting
      rights to the Company to use, license or sublicense, from and after
      Closing, certain Acquired Assets and Registered IP in connection with the
      Drug Repositioning Business;

                  (viii) a license agreement between Purchaser, as licensor, and
      Company, as licensee, in the form attached hereto as Exhibit 1.06(a)(viii)
      (the "Diagnostic Development License Agreement") executed by Company,
      granting rights to the Company to use, license or sublicense, from and
      after Closing, certain Acquired Assets and Registered IP in connection
      with the Diagnostic Development Business;

                  (ix) a master services agreement by and between Purchaser and
      Company in the form attached hereto as Exhibit 1.06(a)(ix), executed by
      Company (the "Drug Repositioning MSA Agreement");

                  (x) a master services agreement by and between Purchaser and
      Company in the form attached hereto as Exhibit 1.06(a)(x), executed by
      Company (the "Diagnostic Development MSA Agreement");

                  (xi) a transition services agreement by and between Purchaser
      and Company in the form attached hereto as Exhibit 1.06(a)(xi), executed
      by Company (the "Transition Services Agreement");

                                       11
<PAGE>

                  (xii) a certificate executed by Company as to the accuracy of
      its representations and warranties as of the date of this Agreement and as
      of the Closing Date in accordance with Section 5.01 and as to its
      compliance with and performance of its covenants and obligations to be
      performed or complied with at or before the Closing in accordance with
      Section 5.02;

                  (xiii) in the event that a Backstop Letter of Credit is not
      delivered at Closing by Purchaser as provided in Section 1.03(b)(iii)(Y),
      Company shall deliver the Security Agreement and the Escrow Agreement each
      executed by Company;

                  (xiv) a certificate as to the good standing of the Company
      issued by the Secretary of State of the State of Delaware; and

                  (xv) a certificate of the Secretary of Company certifying and
      attaching all requisite resolutions or actions of Company's board of
      directors and stockholders approving the execution and delivery of this
      Agreement and the consummation of the Transactions and certifying to the
      incumbency and signatures of the officers of Company executing this
      Agreement and any other documents relating to the Transactions.

            (b) Purchaser and Parent shall deliver to Company:

                  (i) the Closing Cash Payment by wire transfer to an account
      specified by Company;

                  (ii) the Promissory Note executed by Purchaser and Parent;

                  (iii) either (A) the Guarantee executed by Parent and
      Coramandel, and the Security Agreement executed by Purchaser and the
      Escrow Agreement executed by Purchaser and Escrow Agent or (B) a Backstop
      Letter of Credit;

                  (iv) the Assignment and Assumption Agreement executed by
      Purchaser;

                  (v) the (A) Trademark Assignment and (B) Patent Assignment,
      executed by Purchaser;

                  (vi) the Drug Repositioning License Agreement executed by
      Purchaser;

                  (vii) the Diagnostic Development License Agreement executed by
      Purchaser;

                  (viii) the 50 West Watkins Lease Assignment and Assumption
      Agreement executed by Purchaser;

                                       12
<PAGE>

                  (ix) the Sublease executed by Purchase;

                  (x) the Drug Repositioning MSA executed by Purchaser;

                  (xi) the Diagnostic Development MSA Agreement executed by
      Purchaser;

                  (xii) the Transition Services Agreement executed by Purchaser;

                  (xiii) the Third Party IP Assignment and Assumption Agreements
      executed by Purchaser;

                  (xiv) a certificate of the good standing of Purchaser as of
      not more than five (5) days prior to Closing issued by the Secretary of
      State of the State of Delaware and a certificate issued by the government
      of the Republic of India as of a recent date with similar effect with
      respect to Parent;

                  (xv) a certificate executed by Purchaser as to the accuracy of
      its representations and warranties as of the date of this Agreement and
      the Closing Date in accordance with Section 6.01 and as to its compliance
      with and performance of its covenants and obligations to be performed or
      complied with at or before Closing in accordance with Section 6.02; and

                  (xvi) a certificate of the Secretary of Purchaser certifying
      and attaching all requisite resolutions or actions of Purchaser's board of
      directors and stockholders approving the execution and delivery of this
      Agreement and the consummation of the Transactions and certifying to the
      incumbency and signatures of the officers of Purchaser executing this
      Agreement and any other document relating to the Transactions.

                                   ARTICLE II
                   REPRESENTATIONS AND WARRANTIES OF PURCHASER

            Purchaser and Parent hereby represent and warrant to Company as
follows:

            Section 2.0.1. Corporate. Parent is a company duly organized,
validly existing and in good standing under the Company Act, 1956 of the
Republic of India. Purchaser is, or will be within ten (10) days of the date
hereof, a corporation duly organized, validly existing and in good standing
under the Laws of Delaware. Each of Parent and Purchaser have all requisite
corporate power and authority to execute and deliver this Agreement and the
other documents and instruments to be executed and delivered by Parent and
Purchaser pursuant hereto and to carry out the transactions contemplated hereby
and thereby.

            Section 2.0.2. Authority. The execution and delivery of this
Agreement and the other documents and instruments to be executed and delivered
by Parent and Purchaser pursuant hereto and the consummation of the transactions
contemplated hereby and thereby have been duly authorized and approved by the
board of directors of Purchaser and Parent and the shareholders of Purchaser and
Parent. This Agreement constitutes, and, when executed and delivered, the other
documents and instruments to be executed and delivered by Purchaser and Parent
pursuant hereto will constitute, valid and binding agreements of Purchaser and
Parent, enforceable in accordance with their respective terms, except as such
may be limited by bankruptcy, insolvency, reorganization, moratorium or other
Laws affecting creditors' rights generally, and by general equitable principles.

                                       13
<PAGE>

            Section 2.0.3. No Violation. Neither the execution and delivery of
this Agreement or the other documents and instruments to be executed and
delivered by Purchaser or Parent pursuant hereto or thereto nor the consummation
by Purchaser or Parent of the transactions contemplated hereby and thereby
(collectively, the "Transactions") (a) assuming all notices, reports or other
filings described in this Section 2.03 have been given or made, will violate any
Laws or Orders of any Governmental Entity applicable to Purchaser or Parent, (b)
except for filings as would not, individually or in the aggregate, prevent or
materially delay the consummation of the Transactions, will require any
authorization, consent, approval, exemption or other action by or notice to any
Governmental Entity or (c) subject to obtaining the consents described in clause
(b) above, will violate or conflict with, or constitute a default (or an event
that, with notice or lapse of time, or both, would constitute a default) under,
or will result in the termination of, or accelerate the performance required by,
any term or provision of the charter, bylaws or similar organizational documents
of Purchaser or Parent or of any Contract or restriction of any kind or
character to which Purchaser or Parent is a party or by which Purchaser or
Parent or any of their assets or properties may be bound or affected.

            Section 2.0.4. Brokers. Except for o3 Capital Advisers, Pvt. Ltd.,
whose fees will be paid by Purchaser, neither Purchaser, Parent or any of their
directors, officers, employees or agents has retained, employed or used any
investment banking firm, broker or finder in connection with the Transactions or
in connection with the negotiation thereof, nor are any of them responsible for
the payment of any investment banking, broker's or finder's fees.

            Section 2.0.5. Financing. The Purchaser and Parent have available
the funds necessary to consummate the Transactions (including, without
limitation, to make the payments described in Section 1.03), and to pay related
fees and expenses. The letter from ICICI Bank Limited to Parent dated October
10, 2007 attached hereto as Schedule 2.05 (the "Financing Letter") has not been
withdrawn or modified since the date thereof and neither Purchaser nor Parent
has not been notified in writing or verbally of such bank's intention to
withdrawn or modify such letter or the commitment to provide financing contained
therein.

            Section 2.06. Litigation. No action, suit, claim, investigation or
proceeding (legal, administrative or arbitrative) is pending or, to the best of
Purchaser's and Parent's knowledge, threatened against Purchaser or Parent which
seeks to prevent, restrict or delay consummation of the Transactions.

                                       14
<PAGE>

            Section 2.07. Limitations of Company's Representations. Purchaser
and Parent acknowledge and agree that, except as expressly set forth in this
Agreement, the Company has not made any representation or warranty, express or
implied, as to the Company or the Business or as to the accuracy or completeness
of any information regarding the Company or the Business furnished or made
available to Purchaser, Parent or their Representatives. Except as expressly set
forth in this Agreement, the Company is not and shall not be subject to any
Liability to Purchaser or Parent resulting from the distribution to Purchaser or
Parent, or Purchaser's or Parent's use of or reliance on, any such information,
documents or material made available to Purchaser or Parent in any data rooms,
management presentations or in any other form in expectation of, or in
connection with, the Transactions contemplated by this Agreement.

            Section 2.08. Disclosure Documents. None of the information provided
by Purchaser or Parent expressly for inclusion and thereafter included in the
Proxy Statement or any amendment or supplement thereto, will, at the time of
mailing of the Proxy Statement to the stockholders of the Company, at the time
of the meeting at which the Company's stockholders will vote on the
Transactions, or at the time of any amendments thereof or supplements thereto,
contain any untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements made therein, in light of the
circumstances under which they were made, not misleading.

            Section 2.09. Financial Statements. The Balance Sheet of Parent as
of March 31, 2007 and also the Profit and Loss account and each cash flow
statement for the year ended on that date previously delivered to the Company
give the information required by the Company Act, 1956, in the manner so
required and give a true and fair view in conformity with the accounting
principles generally accepted in India as of the date indicated and since such
date no event has occurred with regard to Parent which would constitute a
material adverse effect under the standards for a Material Adverse Effect as
defined herein; provided, however, that in applying the Material Adverse Effect,
subsection (x) thereof shall not apply for the purposes of this Section 2.09.
The balance sheet, income statement and statement of cash flows of Purchaser as
of September 30, 2007 previously delivered to the Company are consistent with
the books and records of the Company and have been prepared in accordance with
the past practices of the Company.

                                   ARTICLE III
                    REPRESENTATIONS AND WARRANTIES OF COMPANY

            Except as set forth in the disclosure schedules to this Agreement,
Company hereby represents and warrants to Purchaser as set forth in this Article
III. Each item disclosed in the disclosure schedules (the "Disclosure
Schedules") to this Agreement shall constitute an exception to the
representations and warranties to which it makes reference and those
representations and warranties herein to which the relevance of the item
disclosed is reasonably apparent, without the necessity of repetitive disclosure
or cross-reference.

                                       15
<PAGE>

            Section 3.01.      Corporate.

            (a) Company is a corporation duly organized, validly existing and in
good standing under the laws of the State of Delaware, and has all requisite
corporate power and authority to own, lease or otherwise hold the Acquired
Assets and to carry on the Business as presently conducted.

            (b) Company is duly qualified or registered to transact business and
is in good standing as a foreign and/or alien corporation in each jurisdiction
in which the failure to be so qualified or registered could reasonably be
expected to have a Material Adverse Effect.

            Section 3.0.2. Authority. Company has the necessary corporate power
and authority to enter into this Agreement and to carry out its obligations
hereunder and to consummate the transactions contemplated hereby. The execution
and delivery of this Agreement by Company and the consummation by Company of the
transactions contemplated hereby have been duly authorized and approved by all
necessary corporate action on the part of Company and no other corporate
proceeding is necessary for the execution and delivery of this Agreement, the
performance by Company of its obligations hereunder and the consummation by
Company of the transactions contemplated hereby, subject only to the adoption of
this Agreement and approval of the Transactions by the requisite affirmative
vote of the stockholders of Company as required by the DGCL at a meeting of the
stockholders of Company. This Agreement has been duly executed and delivered by
Company and, assuming due authorization, execution and delivery by the
Purchaser, constitutes the legal, valid and binding obligation of Company,
enforceable against it in accordance with its terms, except as such may be
limited by bankruptcy, insolvency, reorganization, moratorium or other Laws
affecting creditors' rights generally, and by general equitable principles.

            Section 3.03.      No Violation.

            (a) The execution and delivery of this Agreement by Company do not,
and the performance of this Agreement by Company will not, (i) assuming all
notices, reports or other filings described in clause (i) of Section 3.03(b)
have been given or made, conflict with or violate any Law or Order of any
Governmental Entity applicable to Company or by which any of its property is
bound or affected, (ii) violate or conflict with either the Certificate of
Incorporation or Bylaws of Company or, (iii) except as set forth in Schedule
3.03(a), result in any violation or breach of or constitute a default (or an
event which with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment or cancellation of, or
result in the creation of a lien or encumbrance on any of the property or assets
of Company pursuant to, any note, bond, mortgage, indenture, agreement,
contract, instrument, permit, license, franchise or other obligation to which
Company is a party or by which Company or its property is bound or affected,
except for, in the case of clauses (i) and (iii), conflicts, violations,
breaches or defaults which would not, individually or in the aggregate, have a
Material Adverse Effect or prevent the consummation of the Transactions.

                                       16
<PAGE>

            (b) Except for (i) applicable requirements, if any, of the Exchange
Act, and (ii) filings as would not prevent or materially delay the consummation
of the Transactions, Company is not required to submit any notice, report or
other filing with any Governmental Entity in connection with the execution,
delivery or performance of this Agreement or the consummation of the
transactions contemplated hereby. No waiver, consent, approval or authorization
of any Governmental Entity is required to be obtained or made by Company in
connection with its execution, delivery or performance of this Agreement or the
consummation of the transactions contemplated hereby, except (A) where the
failure to obtain such waivers, consents, approvals or authorizations would not
prevent or materially delay the performance by Company of their respective
obligations under this Agreement or (B) in connection with any submission
required above.

            Section 3.04.      Tax Matters.

            (a) All Tax Returns required to be filed by or on behalf of Company
with respect to the Business or the Acquired Assets have been timely filed. All
such Tax Returns were correct and complete in all material respects. All Taxes
owed by Company have been paid except for Taxes for which payment has not yet
become due. There are no security interests on any of Company's assets that
arose in connection with any failure or alleged failure to pay any Tax.

            (b) Company, with respect to the Business and Acquired Assets, has
duly withheld and paid all Taxes that it is required to withhold and pay in
connection with amounts paid or owing to any employee, independent contractor,
creditor or other third party, except where the failure to withhold or pay Taxes
would not be material to the Business.

            (c) The Tax Returns of Company with respect to the Business or
Acquired Assets that are under audit or have been audited by the Internal
Revenue Service ("IRS") or other applicable Tax authorities since July 1, 2004
are set forth in Schedule 3.04(c). Except as would not be material to the
Business, Company has not received from the IRS or any other applicable Tax
authorities any written notice of underpayment or assessment of Taxes or other
deficiency with respect to the Business or Acquired Assets that has not been
paid or any objection to any Tax Return filed by Company with respect to the
Business or the Acquired Assets. There are no outstanding Contracts or waivers
extending the statutory period of limitations applicable to any Tax Return with
respect to the Business or Acquired Assets.

            (d) No claim has been made by an authority in a jurisdiction in
which Company does not file Tax Returns that it is subject to Tax in that
jurisdiction.

            (e) This Section 3.04 contains all representations and warranties of
the Company with respect to all matters involving Taxes or Laws with respect to
Taxes.

                                       17
<PAGE>

            Section 3.0.5. Absence of Certain Changes. Except as expressly
contemplated by this Agreement or as set forth in Schedule 3.05 or in any SEC
Reports filed and publicly available prior to the date of this Agreement, since
July 1, 2007, (a) the Business has been conducted in the ordinary course
consistent with past practice; (b) there has not been any event, occurrence or
development which would have a Material Adverse Effect on Company or the
Business; (c) there has not occurred any action, event or failure to act, that
if it has occurred after the date of this Agreement would have required the
consent of Purchaser under Section 4.01.

            Section 3.0.6. No Litigation. Except as set forth in Schedule 3.06,
as of the date hereof, there is no Litigation pending or, to Company's
Knowledge, threatened against Company, the Acquired Assets or the Business.
Except as set forth in Schedule 3.06 or in any SEC Reports, as of the date
hereof, there are no Orders relating to the Business or the Acquired Assets.

            Section 3.07.      Compliance   with  Laws  and   Orders;
      Environmental Laws.

            (a) Except as set forth in Schedule 3.07(a), Company (including the
Business and Acquired Assets) is in compliance with all applicable Laws, except
for such instances of noncompliance that would not have a Material Adverse
Effect, and Orders. Except as set forth in Schedule 3.07(a), Company has not
received any written notice of any violation or alleged violation of any Laws or
Orders that have not been resolved. Except as set forth in Schedule 3.07(a), all
reports, filings and returns required to be filed by or on behalf of Company
relating to the Business with any Governmental Entity have been filed.

            (b) Company has all Operating Permits, and all exemptions from
requirements to obtain or apply for any of the foregoing, for the conduct of the
Business (as currently conducted), except where the failure to have such
Operating Permits would not have a Material Adverse Effect. All Operating
Permits are set forth in Schedule 3.07(b), are in full force and effect, except
where the failure to be in full force or effect would not have a Material
Adverse Effect. Except as set forth in Schedule 3.07(b), Company (including the
Business and Acquired Assets) is in compliance with all such licenses, permits,
approvals, certifications, consents and listings, except for such instances of
noncompliance that would not have a Material Adverse Effect.

            (c) Except as would not have a Material Adverse Effect, (i) Company
is in compliance with all applicable Environmental Laws relating to the Business
and the Acquired Assets; (b) Company has all material permits, licenses and
other authorizations required under any Environmental Law relating to the
Business ("Environmental Permits"); (c) Company is in material compliance with
its Environmental Permits; and (d) there are no pending or, to Company's
Knowledge, threatened claims against Company relating to any Environmental Law
or Hazardous Substance relating to the Business. This Section 3.07(c) contains
all representations and warranties of the Company with respect to all matters
involving environmental conditions or Environmental Laws.

                                       18
<PAGE>

            Section 3.08. Title to Properties. Except as set forth on Schedule
3.08, Company has good, valid and marketable title to, or in the case of leased
properties and assets, valid leasehold interests in, all the Acquired Assets and
such assets and properties are owned free and clear of all Liens except for
Permitted Encumbrances.

            Section 3.09.      Tangible Personal Property.

            (a) All furniture, fixtures, computer systems, equipment, laboratory
equipment and other tangible personal property, whether owned or leased, by the
Company and used or held for use primarily in the conduct of the Business during
the twelve (12) months prior to the date of this Agreement (but excluding
embodiments of Business Intellectual Property, Business Information, Information
Assets and Third Party IP) and located either at the 50 West Watkins Mill Road
Facility or Tokyo Facility or in the possession of Business salespeople
(collectively, the "Equipment") shall be delivered "AS IS". Except as provided
on Schedule 3.09(a)(1), notwithstanding the previous sentence, Equipment
essential to providing the products or services provided by the Business in the
ordinary course of its business as conducted during the twelve (12) months prior
to the date of this Agreement (the "Essential Equipment") is in good operating
condition (ordinary wear and tear excepted) and repair. Such personal property
is not held other than in the possession of the Company or the Business
salespeople. Schedule 3.09(a)(2) is a list of the Equipment owned by the Company
that is (i) material for the operation of the Business or (ii) that either (A)
is reflected on the Initial Listing of Assets and Liabilities or was thereafter
acquired (except for assets and properties sold, consumed or otherwise disposed
of in the ordinary course of business since such date), or, (B) with respect to
furniture, fixtures, cubicles, computers, equipment and other tangible assets,
that is or has been located at the 50 West Watkins Mill Road Facility, the Tokyo
Facility or in the possession of the Business salespeople since September 30,
2007, is Equipment which during the twelve (12) months prior to the date of this
Agreement has primarily been used or held for use in the conduct of the Business
(but not including the Retained Assets); provided, that if there is no breach of
Section 3.16(b), the absence of an item included on Schedule 3.09(a)(2) in the
assets delivered at Closing shall not be a breach of this Section 3.09(a), so
long as the Essential Equipment is included in the assets delivered to Purchaser
at Closing.

            (b) The Company has not received notice from any Governmental Entity
that any of the Equipment is not in compliance with all applicable Law, except
for such failures to comply, if any, which have been remedied.

            Section 3.10.      Real Property.

            (a) Company does not own any real property. Schedule 3.10(a) sets
forth a list of all real property leased to and currently used by Company for
the Business (the "Real Property").

            (b) Company is not in breach of or default under the terms of the
Real Property Leases (nor has Company taken or failed to take any action that ,
with notice or lapse of time, or both, would constitute a default) and to
Company's Knowledge the respective landlords of the Real Property Leases are not
in breach of or default under the terms of their Real Property Leases (nor has
either such landlord taken or failed to take any action that , with notice or
lapse of time, or both, would constitute a default). True and correct copies of
the Real Property Leases have been provided to Purchaser.

                                       19
<PAGE>

            (c) Company has not entered into any subleases, licenses or other
agreements relating to the use or occupancy of all or any portion of the Real
Property by any Person.

            (d) the Real Property is sufficient and suited, in all material
respects, for the Business as presently conducted by Company.

            (e) The Real Property is not subject to any procedure or action,
including without limitation eminent domain or condemnation, which may affect
its quiet use. To Company's Knowledge, there is no proposed planning regulation
or decision of a Governmental Entity would result in the taking of all or any
part of the Real Property or that would prevent or hinder the continued use of
the Real Property as it is currently used in the conduct of the Business.

            (f) To Company's Knowledge, the electrical, mechanical, plumbing,
heating, air-conditioning, ventilating, security and other systems serving the
Real Property are in good working order and there are no major repairs (any
single repair costing in excess of $10,000, or repairs costing in aggregate in
excess of $25,000) required to the structure or building systems of the Real
Property.

            (g) Company has not received (i) actual notice of any threatened
special assessments or improvements or activities of any Governmental Entity
either planned, in process, or completed which may give rise to any special
assessment against the Real Property or any portion thereof; or (ii) actual
notice of any judicial or administrative action, or action by any adjacent
landowners, affecting the Real Property that would materially and adversely
impact the operation of the Business.

            Section 3.11. Insurance. Schedule 3.11 sets forth a true and
complete list of all insurance policies carried by Company with respect to the
Business or the Acquired Assets, together with, in respect of each such policy,
the name of the insurer, the policy number, the type of policy, the amount of
coverage and the deductible; provided, however, that none of such insurance
policies is included in the Acquired Assets or Assumed Liabilities.

            Section 3.12.      Material Contracts.
                               ------------------

            (a) As of the date hereof, Schedule 3.12(a) lists all current
Contracts, relating primarily to the Business or the Acquired Assets to which
Company is a party and which fall within any of the following categories (each a
"Material Contract"):

                  (i) all agreements with customers of the Business which
      contain executory obligations of the Business in excess of $300,000 and/or
      a term of more than 24 months from the date hereof;

                                       20
<PAGE>

                  (ii) all agreements with vendors to the Business pursuant to
      which the Business has purchased goods or services in excess of $200,000
      in the 6 months prior to the date hereof;

                  (iii) all agreements, other than Open Purchase Orders or in
      excess of $25,000, pursuant to which the Company and/or the Business is
      required to purchase either a specific dollar amount of goods or services
      or a specific percentage of the Business' requirements;

                  (iv) all agreements with customers of the Business which
      contain "most favored customer," "most favored pricing" or similar terms
      which require the Company and/or the Business to deal with any customer on
      better, equal or similar terms than any other customer that is
      unaffiliated with the first customer;

                  (v) any agreement with any Governmental Entity as a customer;

                  (vi) any agreement requiring an annual payment in excess of
      $100,000 relating to the supply of human tissue samples or to sponsored
      research with entities that have provided or are providing human tissue
      samples;

                  (vii) any distributor, distribution or reseller agreements;

                  (viii) material Contracts not entered into in the ordinary
      course of business;

                  (ix) Contracts relating to any outstanding commitment for
      capital expenditures in excess of $25,000;

                  (x) indentures, mortgages, promissory notes, loan agreements,
      guarantees, letter of credit or other agreements or instruments of Company
      or commitments for the borrowing or the lending by Company of amounts in
      excess of $25,000 providing for the creation of any charge, security
      interest, encumbrance or lien upon any of the Acquired Assets, to the
      extent included in Assumed Liabilities;

                  (xi) any non-competition agreement or any other agreement or
      obligation that purports to limit in any respect the manner in which, or
      the localities in which, the Business may be conducted;

                  (xii) any Contract that Company reasonably believes would
      prohibit or materially delay the consummation of the Transactions (other
      than those requiring consent to assignment as provided Schedule 3.03(a));
      and

                  (xiii) any Contract with any Affiliate that would affect the
      Acquired Assets or Business after Closing (excluding any
      employment-related agreements).

                                       21
<PAGE>

            (b) Company has provided Purchaser with true and complete copies of
the Material Contracts, and any proposed written amendment, supplement or
modification to an existing Material Contract have been made available by
Company to Purchaser. Except as set forth in Schedule 3.12(b), each of the
Material Contracts were entered into in a bona fide transaction in the ordinary
course of business and is legal, valid, binding and enforceable upon Company and
in full force and effect. There is not under any Material Contract: (A) any
existing material default by Company or, to Company's Knowledge, by any other
party thereto, or (B) any event which, after notice or lapse of time or both,
would constitute a default by Company or, to Company's Knowledge, by any other
party, or result in a right to accelerate or terminate or result in a loss of
rights of Company, which default or event could, individually or in the
aggregate, reasonably be expected to result in a liability or cost to Company in
excess of $25,000.

            Section 3.13. Employee and Labor Matters. Except as set forth on
Schedule 3.13, (a) there is no unfair labor practice charge or complaint pending
or, to Company's Knowledge, threatened, against Company relating to the
Business; (b) there is no labor strike, slowdown or stoppage actually pending
or, to Company's Knowledge, threatened, against or affecting Company relating to
the Business nor any secondary boycott with respect to any products or services
of Company relating to the Business; (c) no labor grievance, nor any arbitration
proceeding arising out of or under collective bargaining agreements applicable
to the Company in connection with the Business, is pending; and (d) there are no
administrative charges or court complaints against Company in connection with
the Business concerning alleged employment discrimination or other
employment-related matters pending or threatened before the U.S. Equal
Employment Opportunity Commission or any other Governmental Entity.

            Section 3.14.      Employee Benefit Plans.

            (a) Schedule 3.14(a) sets forth a list of all "employee benefit
plans" (as defined in Section 3(3) of ERISA) and all other employee benefit or
executive compensation arrangements, perquisite programs or payroll practices
applicable to Business Employees, including any such arrangements or payroll
practices providing severance pay, sick leave, vacation pay, salary continuation
for disability, retirement benefits, deferred compensation, bonus pay, incentive
pay, stock options (including those held by directors, employees, and
consultants), hospitalization insurance, medical insurance, life insurance,
scholarships or tuition reimbursements, that are maintained by Company or any
entity within the same "controlled group" as Company, within the meaning of
Section 4001(a)(14) of ERISA (an "ERISA Affiliate") or to which Company or ERISA
Affiliate is obligated to contribute thereunder for current or former employees
of the Business (the "Employee Benefit Plans"); provided, however, that none of
such Employee Benefit Plans or the assets thereof are included in the Acquired
Assets or Assumed Liabilities.

            (b) There are no pending actions, claims or lawsuits which have been
asserted, instituted or, to Company's Knowledge, threatened, against the
Employee Benefit Plans, the assets of any of the trusts in their capacity as
such under such plans or the plan sponsor or the plan administrator, or against
any fiduciary of the Employee Benefit Plans with respect to the operation of
such plans (other than routine benefit claims).

                                       22
<PAGE>

            (c) No Employee Benefit Plan is subject to Section 412 of the Code
or Section 302 or Title IV of ERISA, nor has any of Company, a Company
Subsidiary or an ERISA Affiliate maintained any such plan for the 5 year period
prior to the date of this Agreement. No Employee Benefit Plan is a
"multiemployer plan" within the meaning of Section 4001(a)(3) of ERISA or is a
"single-employer plan" subject to Section 4063 or 4064 of ERISA, nor has
Company, or any ERISA Affiliate maintained or contributed to any such plan at
any time prior to the date of this Agreement.

            (d) With respect to any Employee Benefit Plan that is intended to be
"qualified" under Section 401(a) of the Code:

                  (i) each Employee Benefit Plan has been operated at all times
      in compliance with its terms and Code Section 401(a);

                  (ii) no Employee Benefit Plan is or has been within the five
      (5) year period preceding the date of this Agreement under audit or, to
      Company's Knowledge, investigation by any Governmental Entity; and

                  (iii) Company has provided to the Purchaser a copy of any
      opinion letter or determination letter issued by the IRS with respect to
      such Employee Benefit Plan's qualification.

            (e) As of the date hereof, the Company has not entered into any
written employment agreements with any of the Business Employees and each of the
Business Employees is employed with the Company on an "at-will" basis.

            (f) This Section 3.14 contains all representations and warranties of
the Company with respect to all matters regarding Employee Benefit Plans or Laws
regarding employee or incentive plans.

            Section 3.15.      Intellectual Property.

            (a) Schedule 3.15(a) lists all of the Registered IP and any licenses
or other rights granted to third parties to use the Registered IP. The
Registered IP is registered in the name of Company and Company has the right to
assign the Registered IP to Purchaser pursuant to the terms hereof.

            (b) Except as set forth in Schedule 3.15(b), Company owns all right,
title and interest in and to all material Business Intellectual Property,
and/or, as between Company and its licensor, has a valid and transferable
license to use all material 3rd Party Software Licenses and 3rd Party Databases
subject to the terms of the third party licenses.

            (c) Except as set forth in Schedule 3.15(c), and subject to the
rights of suppliers under agreements with suppliers of biological samples
(including those held in the Biorepository), Company owns all right, title and
interest in and to the Biorepository.

                                       23
<PAGE>

            (d) Except set forth in Schedule 3.15(d), Company is in material
compliance with terms of the public licenses applicable to open source
incorporated by the Company in the Information Assets, excluding open source
incorporated in the Third Party IP.

            (e) Except as set forth in Schedule 3.15(e), the Business
Intellectual Property and the Third Party IP constitute all of the material
Intellectual Property Rights owned, used or held for use by Company primarily in
connection with the Business.

            (f) Except as set forth in Schedule 3.15(f), all renewal fees and
other maintenance fees that have fallen due and for which the payment period has
expired on or prior to the date of this Agreement with respect to Registered IP
have been paid, and no Business Intellectual Property is the subject of any
proceeding before any Governmental Entity, in any jurisdiction, including any
office action or other form of preliminary or final refusal of registration.

            (g) To Company's Knowledge, (i) no claim, suit, action or other
proceeding with respect to any infringement of third party intellectual property
rights, or violation of the respective licenses for the 3rd Party Software, is
threatened in writing or pending against the Company and (ii) the Company's
current use of the 3rd Party Software is consistent with the terms of the
respective licenses to such 3rd Party Software.

            (h) Company has taken reasonable steps necessary to protect the
proprietary status of all material trade secrets and other material confidential
information relating to the Business. Except as described on Schedule 3.15(h),
all employees of the Company who have contributed to or participated in the
conception and development of any material Business Intellectual Property have
executed a Proprietary Information and Inventions Agreement or other agreements
providing for the assignment of Intellectual Property Rights to their work
product for the Business substantially in scope as those contained in the form
attached hereto as Exhibit 3.15(h). Except as described on Schedule 3.15(h),
consultants of the Company who have contributed to or participated in the
conception and development of any of material Business Intellectual Property
have executed an agreement providing for the assignment or license to Customer
of Intellectual Property Rights to their work product for the Business.

            (i) Except as disclosed on Schedule 3.15(i), no written claims, or
to Company's Knowledge unwritten claims, have been made to Company by any person
or entity that (i) Company does not own or have the right to use any
Intellectual Property Right in the conduct of the Business, or (ii) the use of
any Business Intellectual Property by Company, or the conduct of the Business,
infringes upon or misappropriates the Intellectual Property Rights of a third
party, and Company does not know of any valid basis for any such claim.

            (j) To Company's Knowledge, and except as set forth on Schedule
3.15(j), the use of the Business Intellectual Property and the conduct of the
Business by Company does not infringe upon or misappropriate the Intellectual
Property Rights of any Person.

                                       24
<PAGE>

            (k) Except as disclosed on Schedule 3.15(k), to Company's Knowledge,
no Person is infringing or misappropriating any Business Intellectual Property.

            Section 3.16.      Financial Statement.

            (a) The Initial Listing of Assets and Liabilities is consistent with
the books and records of the Company and has been prepared in accordance with
the past practices of the Company.

            (b) As of June 30, 2007, the Net Fixed Assets of the Business
included in the Acquired Assets have a book value equal to Eight Million Eighty
Thousand Dollars ($8,080,000). As of the Closing Date, the book value of the Net
Fixed Assets of the Business shall be equal to at least Eight Million Eighty
Thousand Dollars ($8,080,000), less normal amortization and depreciation since
June 30, 2007. The "Net Fixed Assets of the Business" shall be the plant,
property, equipment and leasehold improvements of the Business as determined by
the Company in accordance with past practices of the Company and consistent with
the books and records of the Company.

            (c) As of the Closing Date, the total Other Current Liabilities of
the Business (less the amount of any increase between the date hereof and the
Closing Date of Other Current Liabilities due to increases in paid time off
accruals) shall not be greater than Eight-Hundred-Sixty-Four Thousand Dollars
($864,000). "Other Current Liabilities of the Business" shall be made up of the
line items of the Business listed on Schedule 3.16(c) hereto.

            (d) Each of the consolidated financial statements (including, in
each case, any related notes thereto) contained in Company's financial
statements contained in its 2006 Annual Report on Form 10-K filed with the SEC
(the "Company Financial Statements"), was prepared in accordance with GAAP
applied on a consistent basis throughout the periods involved (except as may be
indicated in the notes thereto) and (ii) was prepared from and in accordance
with Seller's books and records.

            (e) On the date hereof and on the Closing Date, the Company
Subsidiaries do not and will not have any obligations or liabilities (whether
accrued, contingent or otherwise), in excess of the aggregate amounts set forth
on the Company Subsidiary balance sheets attached hereto as Schedule 3.16(e),
other than liabilities and obligations incurred in the ordinary course of
business since the date of the Company Subsidiaries' balance sheet (which excess
from ordinary course liabilities and obligations for each Company Subsidiary
shall not exceed $100,000).

            Section 3.17. Brokers. Other than Company Financial Advisor, no
broker, finder or investment banker is entitled to any brokerage, finder's or
other fee or commission in connection with the transactions contemplated by this
Agreement based upon arrangements made by and on behalf of Company.

                                       25
<PAGE>

            Section 3.18. Inventory. All Inventories reflected on Company's
financial statements are valued at the lower of cost or market, in accordance
with GAAP applied on a consistent basis throughout the periods indicated. Except
to the extent of inventory reserves reflected on the Company Financial
Statements, the items included in said inventories are (i) normal items of
inventory carried by the Business, and (ii) of a quality and quantity
merchantable in the normal course of business consistent with past practice
(which, for the avoidance of doubt, shall not include expired Inventory).

            Section 3.19.      Customers and Suppliers.
                               ----------------------- -

            (a) Customers. Schedule 3.19(a) sets forth an accurate and complete
list of the ten (10) largest customers of the Business (by volume in dollars of
sales to such customers) for the 12-month period ending as of June 30, 2007 (the
"Material Customers"), and the amount of revenues accounted for by such
customers during such period. None of such Material Customers which are
subscription customers has given notice to Company that it does not intend to
renew its subscription and none of such Material Customer for data generation
services has indicated that upon conclusion of such assignment it will not
consider the Company for future engagements, nor to Company's Knowledge is there
any fact or circumstance that would be reasonably likely to result in any such
change.

            (b) Suppliers. Schedule 3.19(b) sets forth an accurate and complete
list of the ten (10) largest suppliers of Company with respect to the Business
(determined on the basis of dollar volume for the 12-month period ending as of
June 30, 2007 (the "Material Suppliers") and the amounts paid to each Material
Supplier such period ending. None of such Material Suppliers has given notice to
the Company that it intends to cease doing business with the Company with
respect to the Business, nor to Company's Knowledge is there any fact or
circumstance that would be reasonably likely to result in any Material Supplier
reducing or ceasing its relationship with the Business.

            Section 3.20. Transactions with Related Persons. Except as set forth
in Schedule 3.20, no officer or director of Company (any such individuals, a
"Related Person"), or, to the Knowledge of the Company, any Affiliate or member
of the immediate family of any Related Person, is involved in any business
arrangement or relationship with the Company with respect to the Business in
excess of $25,000 per annum, other than employment arrangements entered into in
the ordinary course of business.

            Section 3.21. Product Warranties. To Company's Knowledge, each
product sold or licensed by the Business (the "Business Products") has been in
conformity in all material respects with the specifications (if any) for such
Business Products, all applicable contractual commitments and all applicable
express and implied warranties. No Business Product is subject to any guaranty,
warranty or other indemnity beyond the applicable terms and conditions of the
applicable sales agreement or license or beyond that which may be implied or
imposed by applicable Law.

                                       26
<PAGE>

            Section 3.22. Sufficiency of Assets. Except for the assets in the
Shared Services Division and the Retained Assets, the Acquired Assets
collectively comprise all of the assets and rights necessary for the conduct of
the Business as it has been conducted during the twelve (12) months prior to the
date of this Agreement and is currently being conducted by the Company.

            Section 3.23. Contract Rights. The rights and benefits granted to
Company pursuant to the agreements listed in Section 5(b)(i)-(iv) of Schedule
1.01(b)(1) are not as of the date hereof, and have not within the twelve (12)
months prior to the date hereof, been used by the Company in connection with the
conduct of the Business.

EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE III, NEITHER THE COMPANY NOR ANY
OF ITS AFFILIATES MAKES, OR HAS MADE, ANY REPRESENTATIONS OR WARRANTIES
WHATSOEVER, EXPRESS OR IMPLIED, STATUTORY OR BASED ON COURSE OF DEALING OR USAGE
OF TRADE, RELATING TO THE COMPANY OR THE BUSINESS, ASSETS OR LIABILITIES. ALL
SUCH OTHER REPRESENTATIONS AND WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED
INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY, AND FITNESS FOR A
PARTICULAR PURPOSE. WITHOUT LIMITATION OF THE FOREGOING, NOTWITHSTANDING ANY
OTHER PROVISION OF THIS AGREEMENT, NOTHING IN THIS AGREEMENT IS INTENDED TO BE A
WARRANTY OR REPRESENTATION BY COMPANY OF NON-INFRINGEMENT OF INTELLECTUAL
PROPERTY RIGHTS, OR FREEDOM TO OPERATE UNDER INTELLECTUAL PROPERTY RIGHTS WITH
RESPECT TO THE COMPANY, ANY ACQUIRED ASSETS OR THE BUSINESS, AND ANY AND ALL
SUCH WARRANTIES AND REPRESENTATIONS ARE HEREBY DISCLAIMED IN FULL.

                                   ARTICLE IV
                                    COVENANTS

            Section 4.01. Conduct of Business by Company Pending the Closing.
From the date of this Agreement to the Effective Time, except as required or
permitted by this Agreement or otherwise with the prior written consent of
Purchaser and Company shall (a) carry on the Business in the ordinary course
consistent in all material respects with past practice, (b) use commercially
reasonable efforts to preserve intact in all material respects the Business and
keep available the services of the senior managers of the Business, (c) use
commercially reasonable efforts to preserve in all material respects the
Company's business relationships with principal customers and suppliers of the
Business with which it has business dealings and (d) comply in all material
respects with all Laws applicable to the Company or any of its properties and
assets relating to the Business. Without limiting the generality of the
foregoing, Company shall not, between the date of this Agreement and the
Effective Time, except as expressly required or permitted by this Agreement,
directly or indirectly, do, or commit to do, any of the following without the
prior written consent of Purchaser (which consent shall not be unreasonably
withheld or delayed):

                                       27
<PAGE>

                  (i) Sell, dispose of, transfer, or further encumber any of the
      Acquired Assets, except in the ordinary course of business or pursuant to
      an Acquisition Proposal in accordance with the terms of Section 4.02;

                  (ii) Incur a non-ordinary course obligation or commitment
      which is or will become an Assumed Liability in excess of $50,000 for any
      single obligation or commitment or in the aggregate in the excess of
      $250,000;

                  (iii) Enter into, or modify, amend or terminate, any Material
      Contract other than in the ordinary course of business;

                  (iv) Materially increase the compensation or fringe benefits
      of any of the Business Employees, except as required by contractual
      obligations existing as of the date hereof and except for increases in
      salary or wages in connection with a promotion or change in position
      granted to employees (other than executive officers) of Company in the
      ordinary course of business in accordance with past practice;

                  (v) Except as may be required as a result of a change in Law
      or in generally accepted accounting principles or audit practices, change
      in any material respect any of the accounting methods, practices or
      principles used by the Company relating to the Business; or

                  (vi) Agree to take in writing, any of the actions described in
      this Section 4.01.

            Section 4.02. No Solicitation. Until this Agreement has been
terminated in accordance with Section 8.01, Company shall not, and shall not
permit any of its Affiliates to, and shall cause its Affiliates' officers,
directors, employees, consultants, representatives and other agents, including,
but not limited to, investment bankers, attorneys and accountants (collectively,
"Representatives"), not to, directly or indirectly, (i) solicit, initiate or
knowingly encourage the making of, or take any other action to facilitate any
inquiries or the making of any proposal that constitutes or may reasonably be
expected to lead to, any Acquisition Proposal, (ii) participate in discussions
or negotiations with, or furnish or disclose any nonpublic information to, any
Person (other than Purchaser or their Representatives) in connection with any
Acquisition Proposal, (iii) approve or recommend, or propose to approve or
recommend, any Acquisition Proposal, or (iv) enter into any agreement, letter of
intent or similar document contemplating or otherwise relating to any
Acquisition Proposal; provided, however, that this Section 4.02 shall not
prohibit Company or the Representatives from:

                  (i) participating in discussions or negotiations with, or
      furnishing or disclosing nonpublic information to, any Person in response
      to an unsolicited, bona fide and written Acquisition Proposal that is
      submitted to Company by such Person after the date of this Agreement and
      prior to the Effective Time if (I) none of Company, any of its Affiliates
      or any of the Representatives shall have violated in any material respect
      any of the provisions of this Section 4.02, (II) a majority of the members
      of the Board of Directors of Company determines in good faith, (x) that
      such Person is reasonably capable of consummating such Acquisition
      Proposal taking into account the legal, financial, regulatory and other
      aspects of such Acquisition Proposal and (y) that such Acquisition
      Proposal could reasonably lead to a Superior Proposal, and (III) a
      majority of the members of the Board of Directors determines in good faith
      that failing to take such action would be a breach of its fiduciary duties
      to the Company's stockholders; or

                                       28
<PAGE>

                  (ii) approving or recommending, or entering into, a definitive
      agreement with respect to an unsolicited Acquisition Proposal that is
      submitted to Company after the date of this Agreement and prior to the
      Effective Time if (I) none of Company, any of its Affiliates or any of the
      Representatives have violated in any material respect any of the
      provisions of this Section 4.02, (II) Company provides Purchaser with
      written notice at least three Business Days prior to any meeting of the
      Board of Directors at which such Board of Directors will consider whether
      such Acquisition Proposal constitutes a Superior Proposal, during which
      three-Business Day period Company shall cause its financial and legal
      advisors to negotiate in good faith with Purchaser in an effort to make
      such adjustments in the terms and conditions of this Agreement as would
      enable Company to proceed with the transactions contemplated herein on
      such adjusted terms, (III) notwithstanding such negotiations and
      adjustments pursuant to clause (II) above, the Board of Directors makes
      the determination necessary for such Acquisition Proposal to constitute a
      Superior Proposal, (IV) a majority of the members of the Board of
      Directors determines in good faith that failing to take such action would
      be a breach its fiduciary duties to Company's stockholders, and (V)
      Company does not approve or recommend or enter into a definitive agreement
      with respect to such Acquisition Proposal at any time before the day that
      is the third Business Day after Purchaser receives written notice from
      Company stating that the Board of Directors has determined such
      Acquisition Proposal constitutes a Superior Proposal;

provided, further, that if, in accordance with subsections (i) or (ii) above,
Company determines that an Acquisition Proposal constitutes a Superior Proposal,
then upon termination of this Agreement in accordance with the terms of Section
8.01(d), Company shall pay to Purchaser an amount equal to the sum of $400,000.

            Section 4.03.      Access to Information.

            (a) Except for competitively sensitive information, and subject to
applicable Law, during the period commencing on the date hereof and ending on
the earlier of (i) the Closing Date and (ii) the date on which this Agreement is
terminated pursuant to Section 8.01, Company shall upon reasonable notice,
afford Purchaser, and its Representatives, reasonable access during normal
business hours to the employees, properties, books and records of the Business
so that they may have the opportunity to make such investigations as they shall
desire of the affairs of Business; provided, however, that such investigation
shall not affect the representations and warranties made by Company in this
Agreement. Company agrees to cause its Representatives, in a manner consistent
with the fulfillment of their ongoing duties and obligations, to furnish such
additional financial and operating data and other information and respond to
such inquiries relating to the Business as Purchaser shall from time to time
reasonably request. Notwithstanding the foregoing, nothing herein shall require
Company to disclose any information that would cause a violation of Law or any
confidentiality agreement or contractual requirement or waive any
attorney-client privilege (provided that if Company refrains from disclosing
information requested by Purchaser for any of the foregoing reasons Company
shall so advise Purchaser, including an explanation of the basis for withholding
the information); provided further, that all requests for such access,
inspection or information pursuant to this Section 4.03 shall be made through
Company's General Counsel or such other person as he shall designate in writing
to Purchaser. All nonpublic information provided to, or obtained by, Purchaser
in connection with the transactions contemplated hereby shall be "Confidential
Information" for purposes of the Confidentiality Agreement.

                                       29
<PAGE>

            (b) Except for competitively sensitive information, and subject to
applicable Law, during the period commencing on the date hereof and ending on
the earlier of (i) the Closing Date and (ii) the date on which this Agreement is
terminated pursuant to Section 8.01, Purchaser and Parent shall cause their
Representatives to furnish such information and respond to such inquiries as
Company shall from time to time reasonably request regarding post-closing
integration and operational issues. Notwithstanding the foregoing, nothing
herein shall require Purchaser or Parent to disclose any information that would
cause a violation of Law or any confidentiality agreement or contractual
requirement or waive any attorney-client privilege (provided that if Purchaser
or Parent refrains from disclosing information requested by Company for any of
the foregoing reasons Purchaser and Parent shall so advise Company, including an
explanation of the basis for withholding the information); provided further,
that all requests for such access, inspection or information pursuant to this
Section 4.03 shall be made through Purchaser's Chief Financial Officer or such
other person as he shall designate in writing to Company. All nonpublic
information provided to, or obtained by, Company in connection with the
transactions contemplated hereby shall be Confidential Information for purposes
of the Confidentiality Agreement.

            Section 4.04.      Notification of Certain Matters.

            (a) From the date hereof until Closing, Company shall endeavor to
promptly notify Purchaser in writing if to the Company's Knowledge: (x) any
event, condition, fact or circumstance has occurred, or existed on or prior to
the date of this Agreement and that caused or constitutes a breach of any
representation or warranty made by Company in this Agreement; (y) any event,
condition, fact or circumstance occurs, arises or exists after the date of this
Agreement and that would cause or constitute a breach of any representation or
warranty made by Company in this Agreement if (i) such representation or
warranty had been made as of the time of the occurrence, existence or discovery
of such event, condition, fact or circumstance, or (ii) such event, condition,
fact or circumstance had occurred, arisen or existed on or prior to the date of
this Agreement; and (c) any material breach of any covenant or obligation of
Company. If any event, condition, fact or circumstance arises after the date of
this Agreement that is required to be disclosed pursuant to this Section 4.04
and requires any change in the Disclosure Schedules, or if any such event,
condition, fact or circumstance would require such a change assuming the
Disclosure Schedule were dated as of the date of the occurrence, existence or
discovery of such event, condition, fact or circumstance, then Company shall
promptly deliver to Purchaser an update to the Disclosure Schedule specifying
such change and, when accepted by Purchaser, such update shall be deemed to
supplement or amend the Disclosure Schedule for the purpose of (i) determining
the accuracy of any representation or warranty made by Company in this Agreement
or any closing certificate, or (ii) determining whether any of the conditions
set forth in Article V has been satisfied, unless in accordance with Section
5.07 such update is not accepted by the Purchaser.

                                       30
<PAGE>

            (b) From the date hereof until Closing: (i) Purchaser and Parent
shall promptly notify Company in writing if Purchaser or Parent receives notice,
whether written or verbal, of (A) ICICI Bank's withdrawal or modification of the
Financing Letter or the commitment to provide financing contained therein, (B)
ICICI Bank's intention to withdraw or modify such letter or the commitment to
provide financing contained therein, or (C) any event related to the financing
of the Transaction occurs or fails to occur which would cause the Purchaser or
Parent not to proceed to Closing; and (ii) Company shall promptly notify
Purchaser in writing if Company determines that stockholder approval of the
Transactions will not be or has not been obtained.

            Section 4.0.5. Public Announcements. So long as this Agreement is in
effect, Purchaser and Company shall consult with each other before issuing, and
provide each other a reasonable opportunity to review and comment upon, any
press release or other public statements with respect to this Agreement and the
Transactions and shall not issue, or permit their Affiliates or Representatives
to issue, any such press release or make any such public statement prior to such
consultation, except as may be required by Law (including, but not limited to,
filing of this Agreement on a Current Report on Form 8-K and the filing of a
Schedule 14A and distribution of the related Proxy Statement pursuant to the
federal securities Laws) or in accordance with any listing agreement with, or
the rules, requirements or requests of, any securities exchange on which such
Party's securities are listed or quoted.

            Section 4.0.6. Commercially Reasonable Efforts; Cooperation. Upon
the terms and subject to the conditions hereof, each of the Parties hereto shall
use its commercially reasonable efforts to obtain in a timely manner all
necessary waivers, consents and approvals and to effect all necessary
registrations and filings, and shall use its commercially reasonable efforts to
take, or cause to be taken, all other actions and to do, or cause to be done,
all other things necessary, proper or advisable to consummate and make effective
as promptly as practicable the transactions contemplated by this Agreement,
including, without limitation, (a) cooperating in responding to inquiries from,
and making requests and presentations to, stockholders, customers, suppliers,
regulatory authorities and other third parties, (b) cooperating in the
preparation and filing of the Proxy Statement and (c) promptly making all
regulatory filings and applications and any amendments thereto as are necessary
for the consummation of the transactions contemplated by this Agreement;
provided, however, that (i) nothing in this Section 4.06 shall require a Party
to (x) respond to or defend against any Litigation challenging or relating to
this Agreement or the transactions contemplated hereby, including seeking to
have any stay or temporary restraining order entered, by any court or other
Governmental Entity vacated or reversed, or (y) divest or otherwise transfer or
assign any material assets or cease any material business activities as a
condition of the approval of this transaction by any Governmental Entity, and
(ii) if the Company is unable to obtain consents to assignment of the Sponsored
Research Agreements prior to Closing, Purchaser shall hold the biological tissue
samples provided pursuant to such agreements in escrow (and shall not make use
of such tissue samples until such consents are obtained) and Company and
Purchaser will continue for a reasonable period after Closing to attempt in good
faith to obtain such consents to assignment, or such earlier time as Company
determines it is unable to obtain such consents (but in no event shall Company
be required to pursue such consents for more than ninety (90) days after
Closing) and if Company or Purchaser determine that they will be unable to
obtain such consents, then either Purchaser or Company may require such tissue
samples be removed and destroyed and after such removal and destruction
Purchaser shall certify such removal and destruction to Company; provided,
however, that Purchaser will not be required to (A) remove and destroy in excess
of five percent (5%) of such tissue samples contained in the Biorepository as of
the date of Closing at the direction of the Company or (B) hold in escrow in
excess of ten percent (10%) of such tissue samples contained in the
Biorepository as of the date of Closing.

                                       31
<PAGE>

            Section 4.07.      Retention of Books and Records.

            (a) To the extent documents and records pertaining to the periods
before the Closing are included in the Acquired Assets, after Closing Purchaser
will retain and maintain, in an organized and retrievable manner, all documents
and records pertaining to the periods before the Closing in accordance with
standards of commercial reasonableness. Purchaser will retain and maintain all
machine-sensible records, such as computer tapes, disks, diskettes, etc., which
are considered books and records within the meaning of Code Section 6001.
Purchaser will make available such documents and records, machine sensible
records, computer time, and assistance from Purchaser's personnel as may be
requested by Company in order to expeditiously comply with all pertinent
requests from the Internal Revenue Service, state taxing authorities or other
governmental regulatory agencies that relate to periods prior to the Closing
Date.

            (b) Purchaser and Company agree to retain all Tax returns, related
schedules and work papers and all other material records and other documents
relating to the Company or the Business (the "Documents") for periods prior to,
or including the Closing until December 31, 2014 (the "Document Period") or any
longer period of time required by law as applicable to Purchaser or Company or
that is reasonably requested in writing by Purchaser or Company. During the
Document Period, upon reasonable notice, each of Purchaser and Company will
give, or cause to be given, to the Representatives of the other access to and
permission to copy, at the requesting Party's expense, during normal business
hours, Documents in the custody of such Party and access to its employees with
knowledge of such matters, to the extent reasonably requested by the other Party
in connection with financial reporting matters, audits, legal proceedings,
employee benefit claims, governmental investigations and other reasonable
business purposes; provided, however, that nothing herein will obligate any
Party to take actions that would unreasonably disrupt the normal course of its
business, violate the terms of any contract to which it is a party or to which
it or any of its assets is subject, or grant access to any of its proprietary,
confidential or classified information to the extent not related to the Business
or the Acquired Assets. In no event shall Purchaser (i) file any amended Tax
Return of the Business for any period prior to Closing or (ii) extend the
statute of limitations on assessment of any Tax of the Business for any period
prior to Closing, without the written consent of Company, which cannot be
unreasonably withheld.

                                       32
<PAGE>

            (c) In the event and for so long as any Party is actively pursuing
an affirmative recovery or contesting or defending against any charge,
complaint, action, suit, proceeding, hearing, investigation, claim or demand in
connection with (i) the Transactions or (ii) any fact, situation, circumstance,
status, condition, activity, practice, plan, occurrence, event, incident,
action, failure to act or transaction on or prior to the Closing Date involving
the Business or the Acquired Assets, the other Parties will cooperate with such
Party and its counsel in the pursuit, contest or defense as may be reasonably
requested.

            Section 4.08. Expenses; Proration. Except as otherwise provided
herein, all costs and expenses incurred in connection with this Agreement and
the Transactions shall be paid by the Party incurring such costs and expenses.
Any installment of rent due with respect to any leases assigned in connection
with the Transactions, and any utility or similar charges and assessments
payable with respect to any of the Acquired Assets, and all expenses related to
the operation and maintenance of the Acquired Assets, for the period in which
the Closing occurs shall be adjusted pro rata between Company and Purchaser to
the Closing Date (with Company responsible for periods of time prior to Closing
and Purchaser and Parent responsible for periods of time after Closing). All
costs, expenses, filing and prosecution fees, annuities and maintenance fees
payable from and after the Closing relating to the Registered IP shall be paid
by Purchaser or Parent.

            Section 4.09. Assignment of Contracts, Rights, etc. Notwithstanding
anything contained in this Agreement to the contrary, this Agreement shall not
constitute an agreement to assign the right, title or interest of Company or its
Affiliates in, to or under any contract, license, lease, commitment, sales
order, purchase order or other agreement or any claim or right of any benefit
arising thereunder or resulting therefrom if any attempted assignment thereof,
without the consent of a third party thereto, would constitute a breach thereof
or in any way adversely affect the rights of Company or its Affiliates, unless
and until such consent has been obtained. Company shall use its reasonable best
efforts to obtain, and Purchaser agrees to cooperate with Company in its efforts
to obtain, any required third party consent to the assignment or transfer
thereof to Purchaser. If such consent is not obtained, Company and Purchaser
shall cooperate in any reasonable arrangements designed to provide Purchaser
with the benefits thereunder, including enforcement for the benefit of Purchaser
of any and all rights of Company or any of its Affiliates against such third
party arising out of the cancellation by such third party or otherwise.
Notwithstanding the foregoing, the obligations of Company or any of its
Affiliates under this Section 4.09 shall not include any obligation to make any
material payment or to incur any material economic burden.

                                       33
<PAGE>

            Section 4.10. Transfer Taxes and Recording Fees. All sales, use,
transfer taxes and other non-income taxes and any fees (including deed
recordation fees, Registered IP recordation fees, and filing fees) incurred in
connection with this Agreement and the Transactions (the "Transfer Fees") will
be borne 50% by Purchaser and 50% by Company. Company will cooperate with
Purchaser and Purchaser will cooperate with Company to the extent reasonably
necessary to enable Purchaser or Company, as required, to make such filings and
join in the execution of any tax returns or other documents as may be required
in order for Purchaser and Company to comply with the provisions of this
Section. Upon receipt by Purchaser or Parent of reasonable documentation
provided by Company, Purchaser and Parent will pay directly to Company 50% of
the sales tax incurred in connection with the Transactions so that Company may
remit such taxes directly to the applicable Governmental Entity and Company
covenants to remit such sales tax directly to such Governmental Entity. In the
event that Company receives a refund of any such sales taxes, Company will pay
50% of such returned funds received by the Company to Purchaser or Parent.

            Section 4.11.      Tax Matters.

            (a) Company will be responsible for the preparation and filing of
all federal, state and local franchise, property, payroll, and other non-income
tax returns necessary with respect to the purchase and the ownership of the
Acquired Assets, for all periods as to which such tax returns are due prior to
the date of Closing and Company will make all payments required with respect to
any such tax returns.

            (b) Purchaser will be responsible for the preparation and filing of
all federal, state and local franchise, property, payroll, and other non-income
tax returns necessary with respect to the purchase and the ownership of the
Acquired Assets, for all periods as to which such tax returns are due after the
date of Closing and Purchaser will make all payments required with respect to
any such tax returns; provided, however, that for the avoidance of doubt, such
taxes for the year that includes the Closing Date shall be allocated pro rata
based on the number of days that occur before and after the Closing, with such
taxes being borne Company based on the ratio of the number of days in the
relevant period prior to and including the Closing Date to the total number of
days in the actual taxable period with respect to which such Taxes are assessed,
irrespective of when such Taxes are due, become a lien or are assessed, and such
Taxes being borne by the Purchaser based on the ratio of the number of days in
the relevant period after the relevant Closing Date to the total number of days
in the actual taxable period with respect to which such Taxes are assessed,
irrespective of when such Taxes are due, become a lien or are assessed, and,
further provided, that upon written notice from Purchaser to Company that
Purchaser shall be making a payment for which Company is liable hereunder (which
notice shall include reasonable detail on the amount and calculation of the
pre-Closing portion), Company shall forward to Purchaser, in immediately
available funds, the Company's share of such payment prior to the due date of
such tax.

                                       34
<PAGE>

            Section 4.12.      Mail Received After Closing.

            (a) Following the Closing, Purchaser shall deliver or cause to be
delivered to Company, promptly after receipt by Purchaser, all mail addressed to
Company or any of its Affiliates.

            (b) Following the Closing, Company may receive and open all mail
addressed to Company and may deal with the contents thereof in its discretion to
the extent that such mail and the contents thereof do not relate to the
Business. Company shall deliver or cause to be delivered to Purchaser, promptly
after receipt by Company, all mail, including, without limitation, payments of
accounts or claims receivable, addressed to Company or Purchaser which relates
to the Business.

            Section 4.13.      Personnel Matters.

            (a) Transfer of Employees. The Company has provided a true and
correct list of all of the employees of the Company that devote the primary
portion of their activities as Company employees to the Business, a copy of
which is attached hereto as Schedule 4.13(a). Schedule 4.13(a) also provides the
following information for each such employee: (i) name, (ii) initial employment
date, (iii) job title, (iv) annual base salary, (v) target incentive
compensation for fiscal year 2007, (vi) tenure of employment, (vii) paid time
off accrual, and (viii) exempt/non exempt status with regard to overtime pay.
Offers of employment by Purchaser to any such employees (whether employed prior
to the Transactions by the Company or an Affiliate thereof) listed on Schedule
4.13(a), shall include the following terms and conditions (1) a base salary and
incentive compensation that, in the aggregate, is not less than such person's
current salary and incentive compensation and (2) benefits as are set forth in
Section 4.13(b). All such offers shall be contingent upon the Closing, with
employment to begin immediately following Closing. Such employees that accept
Purchaser's offer of employment and commence work for Purchaser are referred to
herein as the "Business Employees." For clarity, the parties acknowledge and
agree that "incentive compensation" shall not be deemed to include any retention
plans or bonuses provided by Company to such Business Employees.

            (b) Benefit Plans. Purchaser shall, from and after the Effective
Time, (1) until the first anniversary thereof, make available to the Business
Employees benefits under employee benefit plans that are substantially similar
in the aggregate to those provided by the Company to the Business Employees on
the date hereof (the "Company Benefit Plans") and severance benefits on an
individual-by-individual basis as described on Schedule 4.13(b), (2) provide
Business Employees credit for years of service with Company or any of its
subsidiaries or their predecessors prior to the Effective Time for the purpose
of eligibility and vesting under employee benefit plans of Purchaser, (3) to the
extent permitted (whether upon payment by Purchaser of additional premiums or
other terms) under Purchaser's group health plans, cause any and all
pre-existing condition limitations (to the extent such limitations did not apply
to a pre-existing condition under comparable Company Benefit Plans) and
eligibility waiting periods under group health plans of Purchaser to be waived
with respect to Business Employees who become employees of Purchaser or its
subsidiaries (and their eligible dependents) and (4) cause to be reimbursed any
deductibles or out-of-pocket expenses incurred by Business Employees and their
beneficiaries and dependents under Purchaser's group health plan to the extent
such deductibles or out of pocket expenses were already incurred by such
employee (or his or her beneficiaries or dependents) during the prior portion of
the calendar year in which they first participate in Purchaser's health plans,
with the objective that there be no duplication of such deductibles or
out-of-pocket expenses during the year in which the Closing Date occurs.

                                       35
<PAGE>

            (c) WARN Act Notices. Purchaser shall be responsible for and assume
all liability for any and all notices, payments, fines or assessments due to any
government authority, pursuant to any applicable federal, state or local law,
common law, statute, rule or regulation with respect to the employment,
discharge or layoff of employees of the Business as of or within 45 days after
the Closing, including but not limited to the WARN Act.

            (d) COBRA. Company shall be responsible for compliance with all
requirements under Sections 4980B and 9801of the Code and Section 601, et seq.
of ERISA with respect to any (a) Business Employee or (b) dependent of such
Business Employee, in each case who, on or prior to the Closing Date, becomes a
qualified beneficiary within the meaning of Section 4980B(g)(1) of the Code as
the result of any "qualifying event" within the meaning of Section 4980B(f)(3)
of the Code occurring on or prior to the Closing Date or who, on or prior to the
Closing Date, ceases to be covered under Company's group health plan. Purchaser
shall be responsible for compliance with all requirements under Sections 4980B
and 9801 of the Code and Section 601, et seq. of ERISA with respect to any (a)
Business Employee or (b) dependent of such Business Employee, in each case who,
after the Closing Date, becomes a qualified beneficiary within the meaning of
Section 4980B(g)(1) of the Code as the result of any "qualifying event" within
the meaning of Section 4980B(f)(3) of the Code occurring after the Closing Date
or who, after the Closing Date, ceases to be covered under Purchaser's group
health plan.

            (e) 401(k) Rollover. Purchaser shall have amended its 401(k) Plan,
or established a 401(k) Plan if Purchaser does not currently have such a plan,
as necessary to permit the rollover transfer of funds from the Company's 401(k)
Plan to a Purchaser 401(k) Plan and the Purchaser shall accept into such a
Purchaser 401(k) Plan all loans to Business Employees outstanding under the
Company's 401(k) Plan.

            (f) Paid Time Off. To the extent in excess of vacation benefits
available pursuant to Purchaser's vacation policies, Purchaser shall grant
Business Employees accrued and unused paid time off to which such Business
Employees have a right as of the Closing Date pursuant to Company's paid time
off policy. Notwithstanding any other provision in Purchaser's vacation pay
policy, to the extent permitted under Company's paid time off pay policy as of
the Closing Date and to the extent not previously used, Purchaser shall permit
the Business Employees to carry over and use such accrued and unused paid time
off remaining under the Company's policy as in effect on the Closing Date in
future years and Purchaser shall pay such paid time off benefits upon
termination of employment.

                                       36
<PAGE>

            (g) Termination of Employment of Business Employees. As of
immediately prior to Closing, Company shall terminate the employment of each
Business Employee that has accepted an offer of employment with Purchaser.

            (h) Employee Status. The Company shall promptly notify Purchaser of
any Business Employee that terminates employment with the Company or if such an
employee takes a leave of absence from the Company.

            Section 4.14. Non-Solicitation and Non-Compete.

            (a) Non-Solicitation.

                  (i) For a period beginning on the date hereof and ending on
      the last day of the eighteenth (18th) month after the Closing Date (the
      "Nonsolicitation Period"), except with respect to the Business Employees
      listed on Schedule 4.13(a) to whom Purchaser may make offers of employment
      at or prior to Closing that may be accepted by such Business Employees
      during the first thirty (30) days of the Nonsolicitation Period, neither
      Purchaser, Parent, their Affiliates, or Representatives, shall in any
      manner, directly or indirectly (i) solicit or assist any other party to
      solicit any employee of Company or any Affiliate of Company to terminate
      his or her employment with Company or its Affiliate, or (ii) otherwise
      recruit or encourage any such employee to become an employee of, or a
      consultant to, Purchaser or its Affiliate unless Company has consented in
      advance in writing.

                   (ii) During the Nonsolicitation Period, neither Company, its
       Affiliates, or its Representatives, shall in any manner, directly or
       indirectly (i) solicit or assist any other party to solicit any employee
       of Purchaser or any Affiliate of Purchaser to terminate his or her
       employment with Purchaser or its Affiliate, or (ii) otherwise recruit or
       encourage any such employee to become an employee of, or a consultant to,
       Company or its Affiliate unless Purchaser has consented in advance in
       writing.

            (b) Non-Compete. For a period beginning on the date hereof and
ending on the fifth anniversary hereof (the "Restricted Period"), Company and
its Affiliates will not, anywhere in the world engage in the Business as it was
conducted by Company prior to Closing, or have any financial or other interests
in, any person, firm, corporation or line of business that competes with such
Business, directly or indirectly in a material respect; provided, however, that
the following shall not be a violation of this Subsection 4.14(b): (A) ownership
or control by the Company and its Affiliates of less than a 5% interest, as a
passive investor, of the equity securities of a company which is in competition
with the Business; (B) activities associated with the Company's and its
Affiliates' conduct of the Diagnostic Development Business or the Drug
Repositioning Business; (C) ownership of a minority, non-controlling interest in
Xceed Molecular, and (D) activities of the Company and its Affiliates, or a
division or portion of the Company, following their acquisition, whether by
merger, sale of assets, or other business combination by a Person engaged, prior
to such acquisition, directly or indirectly, in whole or in part, in a business
that competes with the Business.

                                       37
<PAGE>

            Section 4.15 Minimum Conditions for Assignment of Lease. Parent will
cause Purchaser to have a minimum net worth of at least Three Million Dollars
($3,000,000) as of the Closing Date.

                                    ARTICLE V
                CONDITIONS TO OBLIGATIONS OF PURCHASER AND PARENT

            The obligations of Purchaser and Parent to consummate the
transactions contemplated by this Agreement shall be subject, to the extent not
waived by Purchaser or Parent, to the satisfaction of each of the following
conditions before or at the Closing:

            Section 5.01. Representations and Warranties. Except for changes
contemplated by this Agreement, the representations and warranties of Company
contained in Article III of this Agreement shall be true and correct in all
material respects as of the date of this Agreement and as of Closing.

            Section 5.02. Performance of this Agreement. Company shall have in
all material respects performed all obligations and complied with all conditions
required by this Agreement to be performed or complied with by it before or at
the Closing.

            Section 5.03. Consents and Approvals. Subject to the provisions of
Section 4.09, all consents, authorizations, orders or approvals which Company is
required to obtain in order for Company to transfer the Acquired Assets to
Purchaser and which are material to the future conduct of the Business by
Purchaser shall have been obtained by Company, including, without limitation,
all waiting periods specified by law with respect thereto shall have passed.

            Section 5.04. Injunction, Litigation, etc. No order of any court or
administrative agency shall be in effect which restrains or prohibits the
consummation of the Transactions, and there shall not have been threatened, nor
shall there be pending, any action or proceeding by or before any Governmental
Entity which is likely to prohibit, delay or successfully challenge the validity
of any of the transactions contemplated by this Agreement.

            Section 5.05. Legislation. No statute, rule or regulation shall have
been enacted which prohibits or restricts the consummation of the Transactions.

            Section 5.06. Deliveries. Company shall have caused the documents
and instruments required by Section 1.06(a) to be delivered (or tendered subject
only to Closing) to Purchaser.

                                       38
<PAGE>

            Section 5.07. Matters Disclosed Pursuant to Section 4.04. Any
amendments to this Agreement or the Disclosure Schedules that are deemed made
pursuant to Section 4.04 of this Agreement, which would reasonably be expected
to have a Material Adverse Effect or have had a Material Adverse Effect, must be
reasonably satisfactory to Purchaser.

            Section 5.08.      Stockholder   Approval.   Company   shall
have obtained the Stockholder Approval.

            Section 5.09.      No Material  Adverse Change.  There shall
not have occurred a Material Adverse Effect.

                                   ARTICLE VI
                      CONDITIONS TO OBLIGATIONS OF COMPANY

            The obligations of Company to consummate Transactions shall be
subject, to the extent not waived by Company, to the satisfaction of each of the
following conditions before or at Closing:

            Section 6.01. Representations and Warranties. Except for changes
contemplated by this Agreement, the representations and warranties of Purchaser
and Parent contained in Article II of this Agreement shall be true and correct
in all material respects as of the date of this Agreement and as of the Closing
Date.

            Section 6.02. Performance of this Agreement. Purchaser and Parent
shall have in all material respects performed all obligations and complied with
all conditions required by this Agreement to be performed or complied with by it
before or at the Closing, to the extent not waived.

            Section 6.03. Stockholder Approval. This Agreement and the
Transactions contemplated hereby shall have been approved and adopted by the
requisite affirmative vote of the stockholders of the Company in accordance with
the DGCL ("Stockholder Approval").

            Section 6.04. Consents and Approvals. All consents, authorizations,
orders or approvals of any Governmental Entity and of other Persons which
Purchaser and Parent are required to obtain in order to consummate the
transactions contemplated by this Agreement shall have been obtained by
Purchaser and Parent and all waiting periods specified by law with respect
thereto shall have passed.

            Section 6.05. Injunction, Litigation, etc. No order of any court or
administrative agency shall be in effect which restrains or prohibits the
consummation of the transactions contemplated hereby or which would limit or
affect Company's rights to transfer the Acquired Assets to Purchaser or
Purchaser's and Parent's ability to consummate the Transactions and there shall
not have been threatened, nor shall there be pending, any action or proceeding
by or before any Governmental Entity which is likely to prohibit, delay or
successfully challenge the validity of any of the transactions contemplated by
this Agreement.

                                       39
<PAGE>

            Section 6.06. Legislation. No statute, rule or regulation shall have
been enacted which prohibits or restricts the consummation of the transactions
contemplated hereby.

            Section 6.07. Deliveries. Purchaser and Parent shall have caused the
documents and instruments required by Section 1.06(b) to be delivered (or
tendered subject only to Closing) to Company.

                                   ARTICLE VII
                                 INDEMNIFICATION

            Section 7.01. Indemnification by Company. Subject to the limitations
contained in this Article VII, Company shall, from and after Closing, indemnify
and hold Purchaser and Parent harmless against all Losses arising out of:

            (a) any breach of a representation or warranty made by Company in
Article III of this Agreement;

            (b) the breach of any agreement of Company contained in this
Agreement; or

            (c) any liability or obligation of Company other than the Assumed
Liabilities.

            Section 7.02. Indemnification by Purchaser and Parent. Subject to
the limitations contained in this Article VII, Purchaser and Parent shall,
jointly and severally, indemnify and hold Company harmless against all Losses
arising out of:

            (a) any breach of a representation or warranty made by Purchaser or
Parent in Article II of this Agreement;

            (b) the breach of any agreement of Purchaser or Parent contained in
this Agreement; or

            (c) any Assumed Liability or the failure by Purchaser or Parent to
discharge any Assumed Liability.

            Section 7.03. Survival Date. The indemnification obligations of each
party (the "Indemnitor") obligated to provide indemnification to the other (the
"Indemnitee") under Sections 7.01 an 7.02 shall lapse and become of no further
force and effect with respect to all claims not made by Indemnitee's delivery to
the Indemnitor of written notice containing details reasonably sufficient to
disclose to Indemnitor the nature and scope of the claim by March 31, 2009 (the
"Claims Period"); provided, however, that notwithstanding the forgoing, the
Claims Period during which a claim for indemnification may be asserted with
respect to:

            (a) Assumed Liabilities or Retained Liabilities shall continue
indefinitely;

                                       40
<PAGE>

            (b) Sections 2.01 (Corporate), 2.02 (Authority), 3.01 (Corporate),
3.02 (Authority), 3.08 (Title to Properties) shall continue indefinitely; and

            (c) Sections 3.04 (Tax Matters) and 3.07(c) (Compliance with Laws
and Orders; Environmental Laws) shall begin on the Closing Date and shall
terminate as of the date of the expiration of the statute of limitations
applicable to the subject matter thereof to which the claim for indemnification
relates.

            (d) Sections 7.01(b) and 7.02(b) shall continue in effect as to each
agreement referenced in such Sections that contemplates performance after the
Closing, in accordance with the terms of such agreements, as long as any claim
for indemnification in respect of a breach of such agreements is brought within
six (6) months after the other party has become aware of facts giving reasonable
notice that a breach has occurred.

Any indemnification obligations arising under Section 7.01 or 7.02 shall lapse
and become of no further force and effect with respect to all claims with
respect to which Indemnitee does not timely give notice to Indemnitor in
accordance with Section 7.06 or Section 7.07(b), as applicable. The intention of
this Section 7.03 is to shorten the applicable statute of limitations for which
to bring claims for indemnity under this Agreement.

            Section 7.04.      Limitations on Indemnification.

            (a) Notwithstanding anything to the contrary herein, the Company
shall not be required to indemnify Purchaser or Parent and Purchaser and Parent
shall not be obligated to indemnify Company unless and until the aggregate
Losses of the Indemnitee exceeds One-Hundred-Fifty Thousand Dollars ($150,000)
(the "Threshold"), and if such Losses are exceeded, only the amount of Losses
above the Threshold, subject to the other limitations provided herein Agreement
provided, however, that Losses arising from the items covered in Sections
1.02(a) (Assumed Liabilities), 1.02(b) (Retained Liabilities), 2.04 (Brokers),
3.17 (Brokers), 4.08 (Expenses; Proration), and 4.10 (Transfer Taxes and
Recording Fees) (collectively, the "Exceptional Items") shall not be subject to
this Section 7.04(a).

            (b) The total indemnification obligations of Company in this
Agreement shall not exceed, in the collective aggregate for Company, One Million
Dollars ($1,000,000.00) (the "Cap"); provided, however, that (i) the Cap shall
not apply to items covered in Sections 1.02(b) (Retained Liabilities), 3.08
(Title to Properties), 3.17 (Brokers), 4.08 (Expenses; Proration), and 4.10
(Transfer Taxes and Recording Fees), (the "Company Uncapped Items") and (ii)
actual fraud committed by Company, shall not be subject to the Cap and such
Damages shall not count towards satisfaction of the Cap.

            (c) The total indemnification obligations of Purchaser and Parent in
this Agreement shall not exceed, in the collective aggregate for Purchaser and
Parent, the Cap; provided, however, that (i) the Cap shall not apply to the
items covered in Sections 1.02(a) (Assumed Liabilities), 2.04 (Brokers), 4.08
(Expenses; Proration), and 4.10 (Transfer Taxes and Recording Fees) (the
"Purchaser Uncapped Items") and (ii) a knowing or intentional misrepresentation
by Purchaser or Parent, or actual fraud committed by Purchaser or Parent, shall
not be subject to the Cap and such Damages shall not count towards satisfaction
of the Cap.

                                       41
<PAGE>

            (d) The parties hereto shall have no liability to the other parties
hereto (for indemnification or otherwise) for the breach of any representation
or warranty to the extent that such other party had actual knowledge at or prior
to the time of Closing that such representation or warranty was not true at the
time of Closing; provided, however, that Purchaser and Parent shall only be
deemed to have actual knowledge in event that Seller can establish with clear
and convincing evidence of actual knowledge by any of Anu Acharya, Subash
Lingareddy or Sujata Pammi based upon written documentation.

            (e) Except for actions grounded in fraud, the parties hereto
acknowledge and agree, the indemnification provisions in this Article VII shall
be the exclusive remedy of the Parties with respect to breaches of the
representations and warranties set forth in this Agreement. As used in this
section, fraud shall not include any claims grounded in an allegation that a
representation or warranty in this Agreement was false, inaccurate or
incomplete. In order to prove fraud, it shall be the burden of the party
alleging fraud to establish that the acts alleged were committed intentionally
and with the specific intent to defraud the other.

            Section 7.05. Definition of Loss. For purposes of this Article VII,
"Losses" shall mean claims, losses, liabilities, damages, deficiencies,
penalties, costs and expenses incurred by an Indemnitee entitled to
indemnification hereunder as a result of a matter giving rise to a claim for
indemnification hereunder, including, without limitation, reasonable expenses of
investigation and reasonable attorneys' fees and expenses incurred in connection
with any action, suit or proceeding ("Legal Action") instituted against the
Indemnitee; provided, however, that Loss shall be determined net of:

            (a) any Tax Benefit (as defined below) inuring to the Indemnitee on
account of such Loss. For purposes of this subsection, "Tax Benefit" shall mean,
after utilizing all deductions, credits and losses otherwise available to it,
any refund of Taxes paid or an actual reduction in the amount of Taxes
(including, without limitation, by deduction, reduction of income by reason of
increased tax basis or otherwise, entitlement to refund, credit or otherwise)
that would otherwise be required to be paid in the particular year. A Tax
Benefit shall be calculated at the then-present value, utilizing a discount rate
of five percent (5%), of such benefit to be realized in the current period or
reasonably anticipated to be realized in any future period by reason of the
facts and circumstances giving rise to the indemnification claim;

            (b) insurance proceeds actually recovered by the Indemnitee in
respect of such matter (it being understood that Indemnitee will pursue such
claims for insurance proceeds in good faith), net of any increase in the
Indemnitee's insurance premiums directly resulting from such recovery and
Indemnitee's reasonable costs in obtaining such recovery; and

                                       42
<PAGE>

            (c) indemnity payments actually received by the Indemnitee from
parties other than the indemnifying party hereunder in respect of such matter
(it being understood that Indemnitee will pursue such claims for payment in good
faith) net of Indemnitee's reasonable costs in obtaining such payments.

Notwithstanding any provision of this Article VII, other than with respect to
claims by Third Parties pursuant to Section 7.07, consequential, incidental and
punitive damages or any damages to the extent attributable to a failure to take
commercially reasonable actions to mitigate damages shall not constitute Losses.

            Section 7.06. Notice of Claims. The Indemnitee shall notify the
Indemnitor in writing promptly after becoming aware of any Losses which an
Indemnitee shall have determined has given rise to a claim for indemnification
under this Article VII. Such written notice (a "Claim Notice") shall include an
estimate of the Losses, if known, the method of computation thereof and a
reference to the specific provisions of this Agreement in respect of which it
seeks indemnification. As soon as practicable after the date of such Claim
Notice, the Indemnitee shall provide the Indemnitor or his or her agents access
to all books and records in the possession or control of the Indemnitee which
the Indemnitor reasonably determines to be related to such claim. If the
Indemnitor notifies the Indemnitee that it does not dispute the claim or the
estimated amount of Losses described in such Claim Notice, or fails to notify
the Indemnitee within thirty (30) days after delivery of such Claim Notice
whether the Indemnitor disputes the claim or the estimated amount of Losses
described in such Claim Notice, the estimated Losses in the amount specified in
the Indemnitee's Claim Notice will be conclusively deemed a Loss owed by the
Indemnitor to the Indemnitee and the Indemnitor shall pay the amount of such
Losses to the Indemnitee. If the Indemnitor has timely disputed its liability
with respect to such claim or the estimated amount of Losses, the dispute shall
be resolved, and the amount, if any, of Losses payable by the Indemnitor to the
Indemnitee shall be determined, in accordance with Section 10.08 below. It is
agreed that no delay on the part of any Indemnitee in notifying the Indemnitor
shall relieve the Indemnitor from its obligations hereunder, except to the
extent said Indemnitor is prejudiced by such failure to give notice. The
provisions of this Section 7.06 do not apply to third party claims referred to
below in Section 7.07.

            Section 7.07.      Third Party Claims.

            (a) Each of the parties must follow the procedures set forth in the
following paragraphs of this Section 7.07 in order to be entitled to
indemnification with respect to claims resulting from the assertion of liability
by persons or entities not parties to this Agreement, including claims by any
Governmental Entity for penalties, fines and assessments.

            (b) The party seeking indemnification shall give prompt written
notice to the party from whom indemnification is sought of any assertion of
liability by a third party which might give rise to a claim by the indemnified
party against the indemnifying party based on the indemnity agreements contained
in this Agreement, stating the nature and basis of the assertion and the amount
thereof, to the extent known; provided, however, that the indemnified party's
failure to give such notice shall not affect any rights or remedies of such
indemnified party hereunder with respect to indemnification for Losses except to
the extent that the indemnifying party is materially prejudiced thereby.

                                       43
<PAGE>

            (c) In the event that any Legal Action is brought against an
indemnified party with respect to which the indemnifying party may have
liability under an indemnity agreement contained in this Agreement, the Legal
Action shall, upon the written agreement of the indemnifying party that it is
obligated to indemnify under such an indemnity agreement, be defended by the
indemnifying party and such defense shall include all appeals or reviews which
counsel for the indemnifying party shall deem appropriate. In any such Legal
Action the indemnified party shall have the right to be represented by advisory
counsel and accountants, at its own expense, and the indemnifying party shall
keep the indemnified party fully informed as to such Proceeding at all stages
thereof, whether or not the indemnified party is represented by its own counsel.

            (d) Until the indemnifying party shall have assumed the defense of
any Legal Action, or if the indemnified and indemnifying parties are both named
parties in such Legal Action and the indemnified party shall have reasonably
concluded that there may be defenses available to it that are materially
different from or in addition to the defenses available to the indemnifying
party (in which case the indemnifying party shall not be entitled to assume the
defense of such Legal Action, but shall remain responsible for its obligation as
an indemnitor), all reasonable out-of-pocket legal and other expenses reasonably
incurred by the indemnified party as a result of such Legal Action shall be
borne by the indemnifying party. In such event, the indemnified party shall make
available to the indemnifying party and its attorneys and accountants, for
review and copying, its books and records relating to such Legal Action and the
parties shall render to each other such assistance as may reasonably be
requested to facilitate the proper and adequate defense of any such Legal
Action.

            (e) The indemnifying party shall not make any settlement of any
claim without the written consent of the indemnified party, which consent shall
not be unreasonably withheld or delayed if the settlement unconditionally
releases the indemnified party from all liabilities and obligations with respect
to such third party action, does not impose injunctive or other equitable relief
against the indemnified party, and does not establish future obligations under
which the indemnified party or any of its Affiliates would be required to
operate; provided, however, that if the indemnified party refuses to provide its
written consent to such a settlement offer, the liability of the indemnifying
party with regard to such claim shall not exceed the amount offered in such
settlement and the indemnified party shall thereafter be responsible for any
liability in excess of the liability that would have arisen under such
settlement.

            Section 7.08.      Subrogation Rights; No Duplication.

            (a) Any Indemnitor required to make a payment under this Article VII
shall be subrogated, to the extent of such payment, to the rights of the entity
to which such payment has been made for reimbursement or indemnification against
third parties relating to the claim on which such payment has been based.

                                       44
<PAGE>

            (b) Notwithstanding anything in this Article VII to the contrary,
the obligations of each Indemnitor and its Affiliates pursuant to this Article
VII shall be without duplication as between entities to which such Indemnitor
and its Affiliates are required to make payments.

            Section 7.09. Exclusive Remedies. The remedies of the parties set
forth in this Article VII are intended to be the sole and exclusive remedies and
sole and exclusive liabilities of the parties for all matters related to
breaches of this Agreement, or the Transactions contemplated by this Agreement,
regardless of the legal theory pursuant to which liability is claimed, except
for (i) the remedies of injunctive relief provided in Section 10.09 with respect
to the specific matters to which such Section relates and (ii) in the case of
fraud.

            Section 7.10. Indemnity Offset. For so long as payment to Seller by
Purchaser or Parent is to be made pursuant to the Promissory Note then, any
payment required hereunder to be made by Seller as the Indemnitor to Purchaser
or Parent as the Indemnitee, may, at Sellers sole and absolute discretion, be
satisfied by offsetting and reducing the outstanding payments remaining on the
Promissory Note. Seller shall within a reasonably period of time after making
such election notify the Purchaser or Parent of such election.

                                  ARTICLE VIII
                        TERMINATION, AMENDMENT AND WAIVER

            Section 8.0.1. Termination. This Agreement may be terminated and the
Transactions may be abandoned at any time prior to the Effective Time:

            (a) By the mutual written consent of Purchaser and Company, by
action of their respective Boards of Directors;

            (b) By either Purchaser or Company if the Closing shall not have
occurred by December 31, 2007; provided, however, that (i) the right to
terminate this Agreement under this subsection (b) shall not be available to (A)
Company where the Closing has not occurred on or before December 31, 2007 by
reason of the failure of any condition precedent under Article V (unless such
failure was within the control of Purchaser or is a failure for reasons beyond
the control of Company (including SEC review of the Proxy Statement or other
Company filings which is ongoing after November 20, 2007, or other Company
filing with the SEC that delays distribution of the Proxy Statement)) or (B)
Purchaser where the Closing has not occurred on or before December 31, 2007 by
reason of the failure of any condition precedent under Article VI (unless such
failure was within the control of Company) and (ii) in the event that Company
receives an Acquisition Proposal less than three Business Days prior to December
31, 2007, Company shall have three Business Days from the date of receipt of
such Acquisition Proposal to determine whether or not such Acquisition Proposal
is a Superior Proposal and Purchaser may not terminate this Agreement during
such three Business Day period without the consent of Company;

                                       45
<PAGE>

            (c) By either Purchaser or Company if any Law shall have been
promulgated that prohibits the consummation of the Transactions or if any
Governmental Entity of competent jurisdiction shall have issued an Order or
taken any other action, in each case permanently restraining, enjoining or
otherwise prohibiting the transactions contemplated by this Agreement and such
Order or other action shall have become final and non-appealable; provided,
however, that the party seeking termination pursuant to this subsection (c) is
not then in breach of any of its representations, warranties, covenants or
agreements contained in this Agreement;

            (d) By either Company or Purchaser, if the Board of Directors shall
have (i) approved or recommended any Acquisition Proposal in respect of Company
or (ii) resolved to take any of the foregoing actions, in each case in
compliance with the provisions contained in this Agreement;

            (e) By either Company or Purchaser if there has been a material
breach by Company, which, if arising due to facts or circumstances occurring
after the date hereof, constitutes a Material Adverse Effect, on the one hand,
or Purchaser, on the other, of such parties' representations or warranties
contained herein or in the due and timely performance of any covenant or
agreement contained herein and the non-breaching party shall have notified the
breaching party of such breach in writing and the breach has not been cured
within thirty (30) days after notice of the breach is received by the breaching
party; or

            (f) By either Company or Purchaser, in the event that Closing shall
not have occurred by January 31, 2008.

            Section 8.0.2. Effect of Termination. In the event of termination of
this Agreement by Company or Purchaser as provided in Section 8.01, (i) this
Agreement shall forthwith become void and have no effect, without any Liability
on the part of Purchaser or Company, except that (i) Section 4.14, Section 10.02
and this Section 8.02 shall survive any termination of this Agreement, (ii) the
Confidentiality Agreement shall survive any termination of this Agreement
pursuant to the terms of such Confidentiality Agreement, and (iii) nothing in
this Section 8.02 shall relieve any Party to this Agreement for Liability for
breach of this Agreement.

            Section 8.0.3. Amendment. This Agreement may be amended by mutual
agreement of the Parties hereto at any time prior to the Effective Time. This
Agreement may not be amended except by an instrument in writing signed by all of
the Parties hereto.

            Section 8.0.4. Extension; Waiver. At any time prior to the Effective
Time, any Party hereto may (a) extend the time for the performance of any of the
obligations or other acts of the other Party hereto, (b) waive any inaccuracies
in the representations and warranties of the other Party hereto contained herein
or in any document delivered pursuant hereto, and (c) waive compliance by the
other Party hereto with any of their agreements or conditions contained herein.
Any agreement on the part of a Party hereto to any such extension or waiver
shall be valid only if set forth in an instrument in writing signed by such
Party. The failure of any Party hereto to assert any of its rights under this
Agreement or otherwise shall not constitute a waiver of those rights.

                                       46
<PAGE>

                                   ARTICLE IX
                             POST-CLOSING AGREEMENTS

            Section 9.01 Severance Obligations. As of immediately prior to
Closing, Company shall terminate the employment of each Business Employee that
has accepted an offer of employment with Purchaser. Purchaser shall reimburse
the Company for all severance payments that would be payable upon termination as
of the Closing Date, that are then or thereafter paid by the Company to any
employee who is not a Business Employee but is included on Schedule 4.13(a)
(such persons being "Non-Continuing Employee"), provided such termination occurs
on or before March 31, 2008. The Purchaser shall pay to the Company at Closing
an amount equal to seventy-five percent (75%) of the aggregate of potential
severance payments due to the Non-Continuing Employees as of the Closing Date.
Within thirty (30) days after Closing, the Company shall provide the Purchaser
with a reconciliation of such amount versus severance payments actually made and
reasonable documentation supporting severance payments made. In the event of any
excess of severance payments over the Purchaser's Closing payment, the Purchaser
shall within ten (10) Business Days of receipt of the reconciliation pay the
Company the amount of the shortfall; and in the event of an excess, within ten
(10) Business Days the Company shall pay the Purchaser the amount of the excess.
From time to time thereafter until April 30, 2008, the Company shall provide the
Purchaser with supporting documentation relating to additional severance made to
Non-Continuing Employees who are terminated on or before March 31, 2008 and
within ten (10) Business Days the Purchaser shall reimburse the Company for such
severance payments. In the event that Purchaser terminates a Business Employee
within sixty days of the Closing Date, Purchaser shall make severance payments
that would be due to such terminated employees consistent with Company's
severance policies specific to a sale of the Business as described on Schedule
9.01(a) hereto (the "Company Severance Policies"). In the event that the total
severance payment obligations of Purchaser to the Company in respect of
employees listed on Schedule 4.13(a), including (i) the Business Employees,
included in the Assumed Liabilities arising prior to the end of the sixtieth day
following the Closing Date in accordance with the Company Severance Policies
(the "Severance Payment Obligations") and (ii) the Non-Continuing Employees who
are terminated by the Company prior to March 31, 2008, are greater than One
Million Dollars ($1,000,000) (the "Severance Liability Cap"), then Company shall
reimburse Purchaser the amount over the Severance Liability Cap not more than
ten (10) Business Days following receipt of notice (the "Severance Payment
Notice") that payments have been made to such employees of the Business together
with a summary of the calculation of payments and basis for all Severance
Payment Obligations. If Company or Purchaser dispute the severance payment
obligations of the other or Purchaser's or Company's compliance with the Company
Severance Policies, Company or Purchaser shall submit an objection notice to the
other not later than ten (10) Business Days following receipt of such notice and
the Parties shall then endeavor for a period of thirty (30) days to resolve the
dispute by agreement. If the Parties are unable to resolve the dispute by mutual
agreement within such thirty (30) day period, then the dispute shall be resolved
by the Independent Accountants in accordance with the procedures described in
Section 1.03(c)(v).

                                       47
<PAGE>

            9.02               Release of Guarantees, Security Agreement and
Escrow Funds.

            (a) If at any time prior to satisfaction of the Promissory Note, the
Purchaser delivers a Backstop Letter of Credit consistent with the terms
provided for in Section 1.03(b)(iii)(Y), then Company shall release the
Guarantee and the Security Agreement delivered pursuant to Section
1.03(b)(iii)(X) and the Promissory Note shall not bear interest at any time
thereafter; provided, that in the event that such a Backstop Letter of Credit is
delivered not more than ninety (90) days after the Closing, any interest accrued
under the Promissory Note shall be forgiven (except interest accruing as a
result of a default under the Promissory Note) and shall no longer be due and
payable by Purchaser to Company.

            (b) If at any time prior to (i) the expiration of the term of the 50
West Watkins Mill Road Lease or (ii) the time at which landlord under such lease
releases the Company from any and all obligations thereunder arising from and
after Closing, the Purchaser delivers a Backstop Letter of Credit meeting the
requirements of Section 1.03(iii)(Y), then the Company shall instruct the Escrow
Agent to deliver the funds held by such Escrow Agent pursuant to the Escrow
Agreement to Purchaser and to terminate the Escrow Agreement.

                                    ARTICLE X
                               GENERAL PROVISIONS

            Section 10.01.     Limitation on Warranties.

            (a) Except for the representations and warranties contained in this
Agreement, or in any instrument delivered pursuant to this Agreement, Company
makes no other express or implied representation or warranty to Purchaser.
Purchaser acknowledges that, in entering into this Agreement, it has not relied
on any representations or warranties of Company other than the representations
and warranties of Company set forth in this Agreement or any instrument
delivered pursuant to this Agreement.

            (b) Except for the representations and warranties contained in this
Agreement or in any instrument delivered pursuant to this Agreement, Purchaser
and Parent make no other express or implied representation or warranty to
Company. Company acknowledges that, in entering into this Agreement, it has not
relied on any representations or warranties of Purchaser or Parent other than
the representations and warranties of Purchaser and Parent set forth in this
Agreement or any instrument delivered pursuant to this Agreement.

                                       48
<PAGE>

            (c) In connection with Purchaser's investigation of Company,
Purchaser received certain projections, including projected statements of
operating revenues and income from operations of the Business and certain
Business plan information. Purchaser acknowledges that there are uncertainties
inherent in attempting to make such estimates, projections and other forecasts
and plans, that Purchaser is familiar with such uncertainties and that Purchaser
is taking full responsibility for making its own evaluation of the adequacy and
accuracy of all estimates, projections and other forecasts and plans so
furnished to it, including, without limitation, the reasonableness of the
assumptions underlying such estimates, projections and forecasts. Accordingly,
Purchaser and Parent hereby acknowledges that Company is making no
representation or warranty with respect to such estimates, projections and other
forecasts and plans, including, without limitation, the reasonableness of the
assumptions underlying such estimates, projections and forecasts.

            Section 10.02. Expenses. Except for Transfer Fees, which are dealt
with in Section 4.10, whether or not the Transactions are consummated, all fees,
costs and expenses incurred in connection with this Agreement and the
transactions contemplated hereby shall be paid by the party incurring such fees,
costs and expenses.

            Section 10.03. Entire Agreement. This Agreement constitutes the
entire agreement and supersedes any and all other prior agreements and
understandings, both written and oral, among the parties with respect to the
subject matter hereof.

            Section 10.04. Assignment. Neither this Agreement nor any of the
rights, interests or obligations hereunder shall be assigned by any of the
parties hereto (whether by operation of Law or otherwise) without the prior
written consent of the other parties hereto (except that Purchaser may assign
its rights, interest and obligations to any Affiliate of Purchaser without the
consent of Company). Subject to the preceding sentence, this Agreement shall be
binding upon, inure to the benefit of and be enforceable by the parties and
their respective successors and assigns.

            Section 10.05. Parties in Interest. This Agreement shall be binding
upon and inure solely to the benefit of each party hereto, and nothing in this
Agreement, express or implied, is intended to confer upon any other Person any
rights or remedies of any nature whatsoever under or by reason of this
Agreement.

            Section 10.06. Validity. If any term or other provision of this
Agreement is invalid, illegal or incapable of being enforced by any rule of Law,
or public policy, all other conditions and provisions of this Agreement shall
nevertheless remain in full force and effect so long as the economic or legal
substance of the transactions contemplated hereby is not affected in any manner
adverse to any party. Upon such determination that any term or other provision
is invalid, illegal or incapable of being enforced, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original
intent of the parties as closely as possible in an acceptable manner to the end
that transactions contemplated hereby are fulfilled to the maximum extent
possible.

                                       49
<PAGE>

            Section 10.07. Notices. All notices and other communications given
or made pursuant hereto shall be in writing (and shall be deemed to have been
duly given or made when received) by delivery in person, by facsimile,
electronic mail, cable, telecopy, telegram or telex (if being sent
electronically, a written confirmation shall be required to be mailed to the
receiving parties), by registered or certified mail (postage prepaid, return
receipt requested), or by express mail through a nationally recognized overnight
courier, in each case to the parties at the following addresses (or at such
other address for a party as shall be specified by like notice):

            (a) If to Company:

                  Gene Logic, Inc.
                  50 West Watkins Mill Road
                  Gaithersburg, Maryland 20878
                  Attention:  Chief Financial Officer
                  Facsimile:  (301) 987-1863
                  E-Mail:  prohrer@genelogic.com

                  With a copy to:

                  Venable LLP
                  575 7th Street N.W.
                  Washington, DC 20004
                        Attention: Ariel Vannier, Esquire
                  Facsimile:  (410) 244-7742
                  E-Mail:   AVannier@Venable.com

            (b) If to Purchaser or Parent:

                  Ocimum Biosolutions Inc.
                  #8765, Guion Road, Suite #G
                  Indianapolis, IN 46268, USA
                  Attention:  Subash Lingareddy
                  Facsimile:  317-228-0700
                  E-Mail:  subash@ocimumbio.co

                  With a copy to:

                  O3 Capital Advisors Pvt. Ltd.
                  #3 Levelle Road,
                  Bangalore 560 001, India
                  Attention:  Shiraz Bugwadia
                  Facsimile:  +91-80-4112-0153
                  E-Mail:  shiraz.bugwadia@o3capital.com

                                       50
<PAGE>

                  And to:

                  Baker Donelson Bearman Caldwell and Berkowitz PC
                         211 Commerce Street, Suite 1000
                  Nashville, Tennessee  37201
                  Attention:  Robert J. Looney, Esq.
                  Facsimile:  615-744-5647
                  E-mail:  blooney@bakerdonelson.com

            Section 10.08.     Law Governing Agreement;  Jurisdiction;
Jury Trial Waiver.

            (a) This Agreement shall be construed and interpreted according to
the internal Laws of the State of Maryland, excluding any choice of Law rules
that may direct the application of the Laws of another jurisdiction. The Parties
agree that the Uniform Computer Information Transactions Act as enacted anywhere
and the United Nations Convention of the International Sale of Goods do not
apply to this Agreement or the Transactions.

            (b) The State or Federal Courts located in the State of Maryland
shall have jurisdiction over any and all disputes between the Parties, whether
in law or equity, arising out of or relating to this Agreement and the
Transactions and the Parties consent to and agree to submit to the jurisdiction
of such courts, except as otherwise provided in Section 9.01 hereof. Each of the
Parties hereby waives and agrees not to assert in any such dispute, to the
fullest extent permitted by applicable Law, any claim that (i) such Party is not
personally subject to the jurisdiction of such courts, (ii) such Party and such
Party's property is immune from any legal process issued by such courts or (iii)
any litigation or other proceeding commenced in such courts is brought in an
inconvenient forum.

            (c) EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES,
AND AGREES TO CAUSE ITS AFFILIATES TO WAIVE, ALL RIGHT TO A TRIAL BY JURY IN ANY
ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT
OR THE TRANSACTIONS CONTEMPLATED HEREBY.

            Section 10.09. Enforcement of Agreement. Each of the parties hereto
acknowledges, understands and agrees that any breach or threatened breach by
such Party or such Party's Affiliates of Sections 4.05, 4.07(b), 4.14 or the
Confidentiality Agreement will cause irreparable injury to the other Party and
that money damages will not provide an adequate remedy therefor. Accordingly, in
the event of any such breach or threatened breach, a non-breaching Party shall
have the right and remedy (in addition to any other rights or remedies available
at law or in equity, including, money damages) to have the provisions of such
Sections 4.05 or 4.07(b) specifically enforced by, and to seek injunctive relief
and other equitable remedies in, any court having competent jurisdiction. Each
Party further agrees to waive any requirement for the securing or posting of any
bond or other security in connection with seeking such remedies.

                                       51
<PAGE>

            Section 10.10. Bulk Sales. To the extent applicable, if at all, the
parties hereto waive compliance with the provisions of the so-called bulk sales
or transfer laws of any jurisdiction in connection with the Transfer of the
Assets pursuant to this Agreement.

            Section 10.11. Headings. The headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.

            Section 10.12. Counterparts. This Agreement may be executed in one
or more counterparts, and by the different parties hereto in separate
counterparts, each of which when executed shall be deemed to be an original but
all of which shall constitute one and the same agreement.

            Section 10.13. Definitions. For purposes of this Agreement, the
term:

            "3rd Party Databases" shall mean the KEGG, SNOMed and BioCarta third
party licensed databases.

            "3rd Party Software Licenses" shall mean the software and software
applications used or held for use primarily in the Business under license from
any Person, subject to the terms of such licenses and excluding the software
licenses on Schedule 10.13(a) hereto.

            "50 West Watkins Lease Assignment and Assumption Agreement" shall
have the meaning set forth in Section 1.06(a)(iv).

            "50 West Watkins Mill Road Facility" shall mean that real property
and improvements leased by the Company prior to the Effective Time and located
at 50 West Watkins Mill Road, Gaithersburg, Maryland.

            "50 West Watkins Mill Road Lease" shall mean that certain Lease
Agreement by and between Company and ARE-50 West Watkins Mill, LLC, a Delaware
limited liability company ("Landlord"), dated July 21, 2000 and all amendments
thereto, including the assignment of Landlord's interest therein to 50West
Watkins Mill Road, LLC.

            "401(k) Plan" shall mean a Defined Contribution Retirement Plan
under Section 401(k) of the Code.

            "Accrued Benefits Liabilities" shall have the meaning set forth in
Section 1.02(a)(ii).

            "Acquired Assets" shall have the meaning set forth in Section 1.01.

                                       52
<PAGE>

            "Acquisition Proposal" shall mean any proposal or offer from any
Person relating to (i) any direct or indirect acquisition or purchase of
substantially all of the assets of Company or of a material part of the assets
of the Business or of over 50% of any class of equity securities of Company,
(ii) any tender offer or exchange offer that, if consummated, would result in
any Person beneficially owning 50% or more of any class of equity securities of
Company, (iii) any merger, consolidation, business combination, sale of
substantially all the assets of the Company or a material part of the Business,
recapitalization, liquidation, dissolution or similar transaction involving
Company or (iv) any other transaction, the consummation of which would
reasonably be expected to impede, interfere with, prevent or materially delay
the Transactions.

            "Affiliate" of a Person shall mean a Person that directly or
indirectly, through one or more intermediaries, controls, is controlled by, or
is under common control with, the first mentioned Person. For the purposes of
this definition, the term "control" means (i) beneficial ownership of at least
fifty percent (50%) of the voting securities of a corporation or other business
organization with voting securities or (ii) a fifty percent (50%) or greater
interest in the net assets or profits or interests of a partnership or other
business organization without voting securities.

            "Agilent Equipment" shall mean the microarray scanner bundle,
hybridization ovens, hybridization chamber, oven rotator, and related software
and accessories generally described in Quote No. 674327 and any amended or
replacement quote therefor issued by Agilent Technologies, to be procured by
Company for use by the Business prior to Closing.

            "Agreement" shall have the meaning set forth in the preamble of this
Agreement.

            "Assigned Patents" shall mean the patents and patent applications
listed on Schedule 10.13(b) hereto which are the patents and patents
applications to be assigned to Purchaser at Closing.

            "Assignment and Assumption Agreement" shall have the meaning set
forth in Section 1.06(a)(ii).

            "Assumed Liabilities" shall have the meaning set forth in Section
1.02.

            "Backstop Letter of Credit" shall have the meaning set forth in
Section 1.03(b)(iii).

            "Bill of Sale" shall have the meaning set forth in Section
1.06(a)(i).

            "Biorepository" shall mean the biological samples and associated
clinical data and any material derived from the manipulation of such samples
used by or under the control of the Business, expressly subject to any rights
of, or ownership by, customers of and suppliers to the Business that have
provided any material, including derivatives thereof, in such repository and
associated clinical data.

                                       53
<PAGE>

            "Board of Directors" shall mean the board of directors of the
Company.

            "Business" shall mean all of Company's activities and operations in
connection with, arising from or relating to (i) the design, development and
operation of gene expression and toxicogenomic databases and related software
tools, toxicogenomic services, microarray data generation and analysis services
(e.g. gene expression, SNP genotyping, miRNA and aCGH), (ii) the licensing of
the foregoing to end-users, including the provision of hosted services to allow
end-users to utilize the databases and (iii) the provision of professional
services related to the foregoing, including without limitation microarray data
generations and analysis services; provided, however, that the term "Business"
does not include the Diagnostic Development Business, the Drug Repositioning
Business or the corporate Shared Services Division..

            "Business Day" means a day other than Saturday, Sunday or any day on
which banks located in the states of New York or Maryland are authorized or
obligated to close.

            "Business Employees" shall have the meaning set forth in Section
4.13(a).

            "Business Information" shall mean, subject to applicable limitations
necessary for compliance with privacy Laws governing employee information and to
any rights of and limitations in agreements with customers and third parties
(including any obligations of confidentiality and non-disclosure), originals or
copies of all books, records, files and documentation, used or held for use
primarily with respect to the Business or the Acquired Assets, including
information, policies and procedures for the conduct of the Business, Equipment
manuals and materials procurement documentation utilized in connection with the
Business, but excluding (i) any Intellectual Property Rights, (ii) employee
data, (iii) the Contracts, and (iv) information collected or generated by the
Shared Services Division, any Company back up tapes and files, and (v) any
information generated or used by the Company's Cambridge, Massachusetts
location.

            "Business Intellectual Property" shall mean Intellectual Property
Rights owned by Company for use primarily in the Business, including without
limitation the Assigned Patents and the Information Assets, excluding Third
Party IP and Retained Assets.

            "Certificate of Incorporation" shall refer to the Certificate of
Incorporation of the Company, as amended as of the date hereof, on filed with
the Secretary of State of the State of Delaware.

            "Claim Notice" shall have the meaning set forth in Section 7.06.

            "Closing" shall have the meaning set forth in Section 1.05.

            "Closing Cash Payment" shall have the meaning set forth in Section
1.03(b)(i).

            "Closing Date" shall have the meaning set forth in Section 1.05.

                                       54
<PAGE>

            "Closing Listing of Assets and Liabilities" shall have the meaning
set forth in Section 1.03(c)(iii).

            "COBRA" shall mean the Consolidated Omnibus Budget Reconciliation
Act of 1985, as amended.

            "Code" shall mean the Internal Revenue Code of 1986, as amended.

            "Company" shall have the meaning set forth in the preamble of this
Agreement.

            "Company Benefit Plans" shall have the meaning set forth in Section
4.13(b).

            "Company Financial Advisor" shall mean Aquilo Partners, Inc.

            "Company Severance Policies" shall have the meaning set forth in
Section 9.01(a).

            "Company Subsidiaries" shall mean Gene Logic K.K. and, if existing
at the Closing Date, Gene Logic Ltd.

            "Company's Knowledge" shall mean the actual knowledge, after
reasonable inquiry, of Larry Tiffany, Charles L. Dimmler, III, F. Dudley
Staples, Jr., Louise Campbell-Blair, and/or Philip L. Rohrer, Jr. acquired in
the performance of such officers' respective duties in the ordinary course of
business.

            "Confidential Information" shall have the meaning set forth in
Section 4.03(a).

            "Confidentiality Agreement" means that certain confidentiality
agreement, effective June 18, 2007, between Purchaser and Company.

            "Contract" shall mean, except for the Real Property Leases and the
Third Party IP agreements, all oral and written contracts, purchase orders,
sales orders, licenses, leases and other agreements, commitments, arrangements
and understandings.

            "Data Management Agreement" shall have the meaning set forth in
Section 1.06(a)(x).

            "DGCL" shall mean the Delaware General Corporation Law.

            "Diagnostic Development Business" shall mean the Company's business
of researching, developing and commercializing diagnostic, prognostic and
monitoring tests for human and animal health care, whether or not such tests
receive regulatory review and approval.

            "Diagnostic Development License Agreement" shall have the meaning
set forth in Section 1.06(a)(vii).

                                       55
<PAGE>

            "Diagnostic Development Master Services Agreement" shall have the
meaning set forth in Section 1.06(a)(x).

            "Disclosure Schedules" shall have the meaning set forth in preamble
of Article III.

            "Documents" shall have the meaning set forth in Section 4.07(b).

            "Document Period" shall have the meaning set forth in Section
4.07(b).

            "Drug Repositioning Business" means the Company's business of (i)
researching, developing and commercializing potential therapies owned by Company
or third parties, or available either off patent or as generics in one or more
regions of the world, for purposes of determining new or additional therapeutic
indications, (ii) expanding indications for currently marketed drugs, (iii)
prioritizing and identifying indications for customers' proprietary compounds in
discovery or preclinical development, (iv) working with third parties to promote
development of compounds in their original indications, but under enhanced
clinical development plans, and/or (v) using the Company's drug indication
seeking technologies for other similar or related uses.

            "Drug Repositioning License Agreement" shall have the meaning set
forth in Section 1.06(a)(vi).

            "Drug Repositioning Master Services Agreement" shall have the
meaning set forth in Section 1.06(a)(ix).

            "Effective Time" shall have the meaning set forth in Section 1.05.

            "Employee Benefit Plans" shall have the meaning set forth in Section
3.12(a).

            "Employee Information" means the employee data listed or described
on Schedule 4.13(a) relating to the Business Employees.

            "Environmental Law" shall mean any federal, state, or municipal
statutes, laws, ordinances, rules or regulations relating to regulation of
pollution or the protection of human health or the environment, including
without limitation the following federal statutes and their state counterparts,
as each may be amended from time to time, and any regulations promulgated
thereunder: the Atomic Energy Act, the Clean Air Act, the Clean Water Act, the
Comprehensive Environmental Response, Compensation, and Liability Act, the
Federal Insecticide, Fungicide, and Rodenticide Act, the Hazardous Materials
Transportation Act, the Occupational Safety and Health Act, the Resource
Conservation and Recovery Act and the Safe Drinking Water Act.

                                       56
<PAGE>

            "Environmental Liabilities of Company" means any and all liabilities
arising in connection with or relating to the Business or the Acquired Assets,
whether accrued, contingent, absolute, determined or determinable, that (i)
arise under or relate to any Environmental Law or to any Environmental Permit in
relation to acts occurring or conditions arising prior to the Effective Time for
such Closing; (ii) relate to actions occurring or conditions existing prior to
the Effective Time, attributable to the acts of Company or any of its
Affiliates; (iii) relate to actions occurring or conditions arising after the
Effective Time, attributable to the acts of Company or any of its Affiliates; or
(iv) arise as a result of (x) the presence of any Hazardous Substance that is
introduced by, or caused by human error of, the employees, agents or
representatives of Company or any of its Affiliates before the Effective Time;
or (y) the presence of any Hazardous Substance caused by a decision by Company
or any of its Affiliates to use, manufacture, generate or release a Hazardous
Substance before the Effective Time.

            "Environmental Permits" shall have the meaning set forth in Section
3.07(c).

            "Equipment" shall mean have the meaning set forth in Section 3.09.

            "Equipment Warranties" shall mean all warranty rights and associated
claims of the Seller with respect to all manufacturers' warranties covering the
Equipment from and after the Closing.

            "ERISA" means the Employee Retirement Income Security Act of 1974,
as amended.

            "ERISA Affiliate" shall have the meaning set forth in Section
3.12(a).

            "Escrow Agent" shall mean The Columbia Bank, located in Columbia,
Maryland, or such other party as the Parties mutually agree.

            "Essential Equipment" shall have the meaning set forth in Section
3.09(a).

            "Exchange Act" shall mean the Securities Exchange Act of 1934, as
amended (including the rules and regulations promulgated thereunder).

            "Financing Letter" shall have the meaning set forth in Section 2.05.

            "GAAP" shall mean United States generally accepted accounting
principles as in effect on the applicable date, consistently applied.

            "Governmental Entity" shall mean any court, arbitrator, department,
commission, board, bureau, agency, authority, instrumentality or other body,
whether federal, state, municipal, county, local, foreign or other.

            "Guarantee" shall have the meaning set forth in Section
1.03(b)(iii).

                                       57
<PAGE>

            "Hazardous Substance" shall mean any pollutant or contaminant or any
hazardous or toxic substance, waste, chemical, or material, including as those
terms are defined in any Environmental Law, and including (a) petroleum and
petroleum products including crude oil and any fractions thereof; (b) natural
gas, synthetic gas, and mixtures thereof; (c) radon; and (d) asbestos and
asbestos-containing materials.

            "Indemnitee" shall have the meaning set forth in Section 7.03.

            "Indemnitor" shall have the meaning set forth in Section 7.03.

            "Independent Accountant" shall have the meaning set forth in Section
1.03(c)(v).

            "Information Assets" shall mean (i) any existing databases of the
Business which comprise genomic, genetic and clinical data, and data from the
public domain, all of which are organized in a manner allowing direct user
access and the ability to export and interrogate such information, including the
following named database products: BioExpress System, ToxExpress System, Ascenta
System, Sciantis System, TRIMS database, BX Freezer database, (ii) any existing
software owned by the Company that is necessary or primarily held for the use of
such databases and their existing information content, analysis tools, or
interfaces allowing databases to be used in conjunction with other data, other
analysis programs, or LIMS based systems, including the following named software
products: Genesis Enterprise System Software, TRIMS Software, GX Connect
Software, ToxEdge Software, and ToxShield Software, and (iii) proprietary
know-how, show how, manufacturing and production methods, processes and
techniques and residual knowledge relating to the foregoing, all of the
foregoing expressly subject to any rights of, or ownership by, customers of and
suppliers to the Business of (a) any material, including derivatives thereof, in
such repository and associated clinical data, (b) any data provided to the
Business or developed by the Business solely for a customer, (c) the software
and databases that comprise the Third Party IP.

            "Initial Listing of Assets and Liabilities" shall have the meaning
set forth in Section 1.03(c)(i).

            "IRS" shall have the meaning set forth in Section 3.04(c).

            "Intellectual Property Rights" shall mean all proprietary and
intellectual property rights recognized by law in any jurisdiction, including
but not limited to the following: (i) all United States and foreign patents and
pending and filed applications therefor (including all provisional, divisional,
continuation in part and reissue patents), utility models, inventors'
certificates and invention disclosures; (ii) all trade secret rights,
proprietary know-how and all other rights in or to confidential business or
technical information, whether patentable, copyrightable or not; (iii) all
writings and other works of authorship, including all copyrights and moral
rights related to each of the foregoing, copyrights, copyright registrations and
applications therefor and all other rights corresponding thereto throughout the
world; (iv) trademarks, service marks, brand names, distinguishing guises, trade
dress rights and similar designation of origin and rights therein and all
goodwill of the Business associated therewith; (v) all registrant's rights to
uniform resource locators, web site addresses and domain names; (vi) industrial
designs; and (vii) rights to limit the access, use or disclosure of confidential
information by any Person; in each case including all registrations of, and
applications to register, any of the foregoing with any Governmental Entity and
any renewals or extensions thereof; the goodwill associated with each of the
foregoing; and any claims or causes of action or defenses arising out of or
related to any of the foregoing.

                                       58
<PAGE>

            "Inventory" shall mean all (i) microarrays (excluding microarrays
listed in paragraph 3 of Schedule 1.01(b)(1), (ii) reagents (excluding reagents
listed in paragraph 3 of Schedule 1.01(b)(1), and (iii) consumables (excluding
consumables listed in paragraph 3 of Schedule 1.01(b)(1) and (iv) tissue samples
acquired to provide data for the BioExpress and ToxExpress databases.

            "Laws" shall mean any applicable statute, law, ordinance, rule or
regulation.

            "Legal Action" shall have the meaning set forth in Section 7.05.

            "Leasehold Improvements" shall mean the improvements described on
Schedule 3.09(a);

            "Liability" means any direct or indirect indebtedness, guaranty,
endorsement, claim, loss, damage, deficiency, cost, expense, obligation or
responsibility, fixed or unfixed, known or unknown, asserted or unasserted,
liquidated or unliquidated, secured or unsecured.

            "Liens" means any mortgages, liens (statutory or otherwise),
security interests, pledges, equities, options, conditional sales contracts,
assessments, levies, easements, reservations, hypothecations, rights-of-way,
rights of reversion, rights of refusal or title encumbrances of any nature
whatsoever on Acquired Assets.

            "Litigation" means any complaint, action, suit, proceeding,
arbitration or other alternate dispute resolution procedure, demand,
investigation or inquiry, whether civil, criminal or administrative.

            "Losses" shall have the meaning set forth in Section 7.05.

            "Material Adverse Effect" shall mean any change, effect, condition,
factor or circumstance that is or is reasonably likely to be materially adverse
to the Business (including its results of operations, properties or financial
condition), Acquired Assets or Assumed Liabilities, taken as a whole; provided,
however, that, in no event shall any of the following be taken into account in
determining whether there has occurred (or whether there is reasonably likely to
be) a Material Adverse Effect: (i) any change or effect resulting from changes
in general economic conditions, conditions in the United States or worldwide
capital markets or any outbreak of hostilities or war (except for any changes
which disproportionately affect the Business, results of operations, properties,
condition, assets or Liabilities of Company, taken as a whole, as compared to
other industry participants); (ii) any change or effect resulting from
conditions generally affecting the industries in which Company conducts the
Business (except for any changes which disproportionately affect the Business,
results of operations, properties, condition, assets or Liabilities of Company
as compared to other industry participants); (iii) any failure by Company to
meet revenue or earnings predictions of equity analysts; (iv) any change or
effect resulting from the announcement of this Agreement or the Transactions;
(v) changes in any Laws applicable to Company after the date hereof (except for
any changes which disproportionately affect the Business, results of operations,
properties, condition, assets or Liabilities of Company as compared to other
industry participants), (vi) changes in GAAP after the date hereof; (vii) any
actions taken, or failures to take action, or such other effects, changes,
occurrences or developments to which Purchaser or Parent has specifically
consented in writing after the date hereof and prior to such actions, failures,
effects, changes, occurrences or developments; (viii) terrorist activities or
the material commencement or worsening of hostilities or war; (ix) changes in
Company's relationships with existing vendors, customers or suppliers resulting
from Company's public announcement of impairment charges (but only to the extent
such impairment charges do not exceed amounts or potential amounts made known to
Purchaser or Parent prior to the execution of this Agreement); or (x) the trend
of declining revenue of the Business from January 1, 2007 until the date hereof.

                                       59
<PAGE>

            "Material Contract" shall have the meaning set forth in Section
3.10(a).

            "Open Purchase Orders" shall mean all purchase orders or other
commitments issued by Company in the ordinary course of business before the
Closing Date for the supply of tangible assets (including Inventory) and
services to or for use in the Business to the extent that such tangible assets
have not already been supplied and accepted by, or such services performed for,
the Business on or prior to the Effective Time.

            "Operating Permits" shall mean, except for the Environmental
Permits, all licenses, permits, approvals, certifications, consents and listings
of all Governmental Entities and all certification organizations required, and
all exemptions from requirements to obtain or apply for any of the foregoing,
necessary for the conduct of the Business (as currently conducted as conducted
within the last twelve (12) months).

            "Orders" shall mean any order, writ, injunction, judgment, plan or
decree.

            "Parent" shall have the meaning set forth in the preamble of this
Agreement.

            "Party" and "Parties" shall have the meanings set forth in the
preamble of this Agreement.

            "Patent Assignment" shall have the meaning set forth in Section
1.06(a)(iii)(B).

                                       60
<PAGE>

            "Permitted Encumbrances" shall mean (i) Liens for real or personal
property taxes which are not yet due and payable, (ii) mechanic's, carrier's,
workmen's, repairmen's or other similar statutory Liens arising or incurred in
the ordinary course of business, (iii) minor imperfections of title, conditions,
easements and reservations of rights, (iv) Purchase Money Security Interests in
amounts less than $25,000, and (v) Liens and operating leases that are listed on
Schedule 10.13(c), and (vi) restrictions on the use, disclosure or transfer of
Acquired Assets or information imposed by contract or by confidentiality
obligations to third parties that are disclosed on the appropriate Schedule to
this Agreement.

            "Person" shall mean an individual, corporation, partnership,
association, trust, any unincorporated organization or group (within the meaning
of Section 13(d)(3) of the Exchange Act).

            "Prepaid Expenses" shall mean all the prepaid expenses of Company
relating to the Business or the Acquired Assets, excluding security deposits or
advances deposited or paid by or on behalf of Company as lessee or sublessee or
pursuant to any Real Property Lease.

            "Promissory Note" shall have the meaning set forth in Section
1.03(b)(ii).

            "Proxy Statement" shall mean a proxy statement to be sent to the
stockholders of Company in connection with a meeting of Company stockholders to
consider this Agreement and the Transactions, as amended or supplemented.

            "Purchase Price" shall have the meaning set forth in Section
1.03(a).

            "Purchase Price Adjustment" shall have the meaning set forth in
Section 1.03(c)(ii).

            "Purchaser" shall have the meaning set forth in the preamble of this
Agreement.

            "Purchase Money Security Interest" shall have the meaning given to
such term in Section 9-103 of the Commercial Law Article of Annotated Code of
Maryland.

            "Real Property" shall have the meaning set forth in Section 3.08(b).

            "Real Property Leases" shall mean the 50 West Watkins Mill Lease and
the Tokyo Lease.

            "Registered IP" shall mean all United States, international and
foreign Intellectual Property Rights that are the subject of an application,
certificate, filing, registration or other document issued, filed with, or
recorded by any state, government or other public legal authority and that are
owned by the Company and used or held for use primarily in connection with the
Business.

            "Representatives" shall have the meaning set forth in Section 4.02.

                                       61
<PAGE>

            "Retained Assets" shall have the meaning set forth in Section 1.01.

            "Retained Liabilities" shall have the meaning set forth in Section
1.02.

            "SEC" shall mean the United States Securities and Exchange
Commission.

            "SEC Reports" shall mean all forms, reports, schedules, proxy
statements, registration statements and other documents (including all exhibits
thereto) required to be filed with the SEC by Company.

            "Security Agreement" shall have the meaning set forth in Section
1.03(b)(iii).

            "Severance Liability Cap" shall have the meaning set forth in
Section 9.01(a).

            "Severance Payment Notice" shall have the meaning set forth in
Section 9.01(a).

            "Severance Payment Obligations" shall have the meaning set forth in
Section 9.01(a).

            "Shared Services Division" consists of the Company's corporate and
support functions that are not particular to any operating division and include
the office of the Company's Chief Executive Officer and the officers and other
personnel performing the following functions: finance, legal, human resources,
purchasing, facilities maintenance, management information systems and investor
relations.

            "Sponsored Research Agreements" shall mean those agreements (however
titled and including related documents such as task orders, research plans and
material transfer agreements) pursuant to which Company has obtained biological
samples and related clinical data for the primary purpose of generating data
that can be incorporated into its commercially available databases.

            "Stockholder Approval" shall have the meaning set forth in Section
6.03.

            "Subsidiary" shall mean any corporation or other legal entity of
which another corporation or other legal entity (either alone or through or
together with another Subsidiary) (a) owns, directly or indirectly, more than
50% of the stock or other equity interests the holders of which are generally
entitled to vote for the election of the board of directors or other governing
body of such corporation or other legal entity, or (b) in the case of
partnerships, serves as a general partner, or (c) in the case of a limited
liability company, serves as managing member or (d) otherwise has the ability to
elect a majority of the directors, trustees or managing members thereof.

            "Superior Proposal" shall mean a bona fide proposal made by any
Person to acquire all of the issued and outstanding shares pursuant to a tender
offer or a merger or to acquire substantially all of the assets of Company or a
material part of the assets of the Business on terms and conditions that a
majority of the members of the Board of Directors determines in good faith,
taking into account all the terms and conditions of such proposal (including,
without limitation, any expense reimbursement provisions, termination fees and
conditions), is more favorable to Company's stockholders, from a financial point
of view, than the transactions contemplated hereby.

                                       62
<PAGE>

            "Tax Returns" shall mean any return, declaration, report, estimate,
claim for refund, or information return or statement relating to, or required to
be filed in connection with, any Taxes, including any schedule, form, attachment
or amendment.

            "Tax" or "Taxes" shall mean any federal, state, county, local,
territorial, provincial, or foreign income, net income, gross receipts, single
business, unincorporated business, license, payroll, employment, excise,
severance, stamp, occupation, premium, windfall profits, environmental
(including taxes under Section 49A of the Code), customs duties, capital stock,
franchise, profits, gains, withholding, social security (or similar), payroll,
unemployment, disability, workers compensation, real property, personal
property, ad valorem, replacement, sales, use, transfer, registration, value
added, alternative or add-on minimum, estimated, or other tax of any kind
whatsoever, including any interest, penalty, or addition, whether or not
disputed and whether or not disputed and whether imposed by Law, Order, Contract
or otherwise.

            "Third Party IP" shall mean the rights of the Company to (i) the 3rd
Party Software Licenses, (ii) the 3rd Party Databases, and (iii) other licensed
Intellectual Property Rights held by the Company for use solely in connection
with the Business other than rights referred to in clauses (i) and (ii), subject
in each case to the terms of the applicable licenses.

            "Threshold" shall have the meaning set forth in Section 7.04(a).

            "Tokyo Facility" shall mean that real property and improvements
leased by the Company prior to the Effective Time and located at Cerulean Tower
15th Floor, 15th Floor, Cerulean Tower, 26-1 Sakuragaoka-cho, Shibuya-ku, Tokyo.

            "Tokyo Lease" shall mean that certain Lease Agreement by and between
Company and The Executive Centre Japan K.K. for a term commencing on November
15, 2004 and all amendments thereto and extensions thereof for Unit Number
Seven located at Cerulean Tower 15th Floor, 15th Floor, Cerulean Tower, 26-1
Sakuragaoka-cho, Shibuya-ku, Tokyo.

            "Tokyo Lease Assignment and Assumption Agreement" shall have the
meaning set forth in Section 1.06(a)(v).

            "Total Cash Consideration" shall have the meaning set forth in
Section 1.03(a).

            "Trademark Assignment" shall have the meaning set forth in Section
1.06(a)(iii)(A).

                                       63
<PAGE>

            "Transactions" shall have the meaning set forth in Section 2.03.

            "Transfer Fees" shall have the meaning set forth in Section 4.10.

            "Transition Services Agreement" shall have the meaning set forth in
Section 1.06(a)(xi).

            "Unbilled Receivables" means the unbilled receivables of the
Business. Unbilled Receivables is comprised of both Debit and Credit Balances,
all accounted for in accordance with the books and records of the Company and
applying the same methodology, accounting principles, policies and practices
used in preparing the Initial Listing of Assets and Liabilities consistent with
the past practice of the Company. "Credit Balances" represent prepayments for
future services under the terms of individual customer contracts. "Debit
Balances" represent amounts relating to services performed by the Business for
which the Company does not have the right to bill the customer until the next
milestone is met or a contract modification is approved.

                                       64
<PAGE>

            IN WITNESS WHEREOF, Purchaser, Parent and Company have caused this
Agreement to be executed as of the date first written above by their respective
officers thereunto duly authorized.

                                       GENE LOGIC INC. (Company):

                                       By:      /s/ Charles L. Dimmler, III
                                                ------------------------------
                                       Name:    Charles L. Dimmler, III
                                       Title:   Chief Executive Officer
                                                and President

                                       OCIMUM BIOSOLUTIONS LIMITED
                                       (Parent):

                                       By:      /s/ Subash Lingareddy
                                                ------------------------------
                                       Name:    Subash Lingareddy
                                       Title:   President and Chief
                                                Financial Officer

                                       OCIMUM BIOSOLUTIONS INC.
                                       (Purchaser):

                                       By:      /s/ Subash Lingareddy
                                                ------------------------------
                                       Name:    Subash Lingareddy
                                       Title:   President and Chief
                                                Financial Officer

                                       1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}]]